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ABSTRACT 
Estrogen and the estrogen receptor alpha (ERα) are traditionally considered as the main etiological 
factors in breast cancer. However, other members of the steroid receptor family, including ERβ and 
the androgen receptor (AR) have also been shown to play a role. It is known that ERα drives breast 
cancer cell proliferation, while ERβ antagonizes ERα-mediated effects. Moreover, the AR, which is 
expressed in the majority of ER-positive breast cancer tumours, has been shown to inhibit the 
transcriptional activity of ERα and increase ERβ expression when activated by the potent natural 
androgen, 5α-dihydrotestosterone (DHT). Together, this suggests that the AR is associated with a 
good prognosis in ER-positive breast cancer. The question that arises is whether all agonists binding 
to the AR would elicit similar effects. This is particularly relevant to progestins used by millions of 
women in contraception and menopausal hormone therapy (HT), as a number of progestins are known 
to bind to the AR, with some displaying androgenic properties similar to DHT and others displaying 
anti-androgenic properties. For example, progestins like medroxyprogesterone acetate (MPA), 
norethisterone acetate (NET-A), and levonorgestrel (LNG) have been shown to be as potent and 
efficacious as the natural androgen DHT, while others like nestorone (NES) and nomegesterol acetate 
(NOMAC) display anti-androgenic properties similar to the natural progestogen, progesterone (P4). 
It is noteworthy that MPA, NET-A and LNG have all been associated with an increased risk of breast 
cancer. However, the underlying mechanisms whereby these progestins contribute to increased breast 
cancer risk has not been established. In this study, our main aim was to investigate whether 
androgenic progestins, unlike anti-androgenic progestins, would elicit similar effects as DHT and the 
synthetic androgen, mibolerone (Mib), on ERβ and ERα expression in human breast cancer cell lines. 
First however, we used mammalian two-hybrid assays to investigate the ability of the progestins to 
induce the ligand-dependent interaction between the NH2- and COOH-terminal domains (N/C 
interaction) of the AR, and showed that progestins elicit different conformations in the receptor. 
Western blot analysis showed that unlike the androgens that increased AR protein levels, the 
progestins did not influence AR protein levels in the MCF-7 BUS or MDA-MB-453 breast cancer 
cells. Quantitative real-time PCR (qPCR) showed that like the androgens, MPA, NET-A and LNG 
all increased ERβ mRNA expression in the MDA-MB-453 cell line, while P4, NES and NOMAC did 
not. Moreover, by using the AR antagonist, hydroxyflutamide, we showed that these effects were 
mediated by the AR. Although these results suggest another mechanism by which the AR may inhibit 
breast cancer cell growth, the results should be interpreted with caution as we show that the AR-
mediated effects of the androgens and androgenic progestins, in fact, increased proliferation of the 
MCF-7 BUS and T47D breast cancer cell lines. Unlike, Mib and DHT, which decreased ERα mRNA 
expression via the AR, MPA, NET-A and LNG had no effect on ERα expression. Although the 
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precise physiological implications of these preliminary results remain to be determined, our findings 
highlight the fact that the role of progestins in breast cancer is not straightforward. Moreover, these 
findings contribute to our understanding of crosstalk between the AR and ER subtypes in breast 
cancer.   
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OPSOMMING 
Estrogeen en die estrogeenreseptor alfa (ERα) word tradisioneel beskou as die hoof etiologiese 
faktore in borskanker. Ander lede van die steroïedreseptor familie, insluitende ERβ en die androgeen 
reseptor (AR), speel egter ook 'n rol in borskanker. Dit is bekend dat ERα borskankerproliferasie dryf, 
terwyl ERβ hierdie ERα-gemedieërde effekte teenwerk. Verder is dit bewys dat die AR, wat in die 
meerderheid van ER-positiewe borskankergewasse uitgedruk word, die transkripsionele aktiwiteit 
van ERα inhibeer en die uitdrukking van ERβ verhoog wanneer dit geaktiveer word deur die 
natuurlike androgeen, 5α-dihidrotestosteroon (DHT). Saam dui dit daarop dat die AR geassosieer 
word met 'n goeie prognose in ER-positiewe borskanker. Die vraag wat egter ontstaan is of alle 
agoniste wat aan die AR bind soortgelyke effekte sal ontlok. Hierdie vraag is veral van toepassing op 
progestiene wat deur miljoene vroue gebruik word in voorbehoedmiddels en menopausale 
hormoonterapie (HT), aangesien baie van hierdie progestiene aan die AR kan bind, en óf androgeen 
eienskappe soortgelyk aan DHT vertoon, óf anti-androgeniese eienskappe. Byvoorbeeld, progestiene 
soos medroksieprogesteroon asetaat (MPA), noretisteroon asetaat (NET-A) en levonorgestrel (LNG) 
is bewys om ewe sterk en doeltreffend as die natuurlike androgeen DHT te wees, terwyl ander soos 
nesteroon (NES) en nomegesterolasetaat (NOMAC) anti-androgeniese eienskappe soortgelyk aan die 
natuurlike progestogeen progesteroon (P4) vertoon. Dit is opmerklik dat MPA, NET-A en LNG almal 
verband hou met 'n verhoogde risiko van borskanker. Die onderliggende meganismes waardeur 
hierdie progestiene bydra tot 'n verhoogde borskanker risiko is egter nog nie vasgestel nie. In hierdie 
studie was ons hoofdoel om vas te stel of androgeniese progestiene, in teenstelling met anti-
androgeniese progestiene, soortgelyke effekte as DHT en die sintetiese androgeen, miboleroon (Mib), 
op ERβ- en ERα-uitdrukking in menslike borskanker sellyne sal hê. Eerstens het ons die vermoë van 
die progestiene ondersoek om die ligand-afhanklike interaksie tussen die NH2- en COOH-terminale 
domeine (N/C interaksie) van die AR te induseer. Ons het gewys dat progestiene verskillende 
konformasies in die reseptor ontlok. Deur gebruik te maak van westernklad-analise het ons gewys dat 
progestiene, in teenstelling met die androgene wat AR-proteïenvlakke verhoog het, geen invloed op 
AR-proteïenvlakke in die MCF-7 BUS of MDA-MB-453 borskankerselle gehad het nie. 
Kwantitatiewe intydse PKR (qPKR) het getoon dat MPA, NET-A en LNG, nes die androgene, ERβ 
mRNA-uitdrukking in die MDA-MB-453-sellyn verhoog, terwyl P4, NES en NOMAC geen effek 
getoon het nie. Verder, deur die gebruik van die AR antagonis, hidroksieflutamied, het ons getoon 
dat hierdie effekte deur die AR bemiddel is. Alhoewel hierdie resultate 'n ander meganisme voorstel 
waarmee die AR borskankergroei kan inhibeer, moet dié resultate met omsigtigheid geïnterpreteer 
word, aangesien ons toon dat die AR-gemedieërde effekte van die androgene en androgeniese 
progestiene inderdaad die proliferasie van die MCF-7 en T47D-sellyne verhoog. In teenstelling met 
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Mib en DHT, wat via die AR die ERα mRNA uitdrukking verlaag, het MPA, NET-A en LNG geen 
effek op ERα-uitdrukking gehad nie. Alhoewel die presiese fisiologiese implikasies van hierdie 
voorlopige resultate nog bepaal moet word, beklemtoon ons bevindings die feit dat die rol van 
progestiene in borskanker nie eenvoudig is nie. Daarbenewens dra hierdie bevindinge by tot ons 
begrip van wisselwerking tussen die AR en ER subtipes in borskanker. 
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Literature Review 
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1.1 Introduction 
Progestins are synthetic compounds designed to mimic the biological actions of the natural 
progestogen, progesterone (P4), via the progesterone receptor (PR). Derived from different parent 
compounds, progestins were designed in four consecutive generations (Schindler et al. 2003; Sitruk-
Ware 2006; Africander et al. 2011a; Stanczyk et al. 2013). The first generation progestins include 
medroxyprogesterone acetate (MPA) and norethisterone enanthate (NET-EN) or norethisterone 
acetate (NET-A), while levonorgestrel (LNG) forms part of the second generation. Gestodene (GES), 
a derivative of LNG, is classified as a third generation progestin, while the fourth and newest 
generation include drospirenone (DRSP), nestorone (NES) and nomegesterol acetate (NOMAC). 
 
Progestins have a wide range of therapeutic applications, the most common being its use in 
contraception and hormone therapy (HT) (Sitruk-Ware, 2006). In contraception, progestins suppress 
ovulation and inhibit sperm penetration in order to prevent pregnancy (Sitruk-Ware, 2006), while 
progestins used in HT prevent estrogen-induced endometrial hyperplasia in menopausal women with 
an intact uterus (Sitruk-Ware, 2006). Other therapeutic applications of progestins include the 
treatment of gynecological disorders like polycystic ovary syndrome (PCOS) (Archer and Chang, 
2004; Guido et al., 2004; Ehrmann, 2005) and endometriosis (Harrison and Barry-Kinsella, 2000; 
Irahara et al., 2001; Vercellini et al., 2003). Despite their therapeutic benefits, the use of some 
progestins are associated with side-effects such as an increased risk for cardiovascular disease, venous 
thromboembolism (VTE), increased susceptibility to genital tract infections, and increased risk of 
invasive breast cancer (Mostad et al., 2000; Rossouw et al., 2002; Beral et al., 2003; Fournier et al., 
2008; Morrison et al., 2010). 
 
Many of these side-effects are suggested to be due to the cross-reactivity of progestins with steroid 
receptors other than the PR (Hapgood et al. 2004; Sitruk-Ware 2006; Africander et al. 2011a; 
Stanczyk et al. 2013; Louw-du Toit et al. 2017a). For example, it has been shown that MPA and GES 
exhibit glucocorticoid agonist activity, while P4, NET-A, LNG and DRSP do not (Africander et al. 
2011b; Stanczyk et al. 2013; Koubovec et al. 2005). Furthermore, DRSP (Krattenmacher, 2000), 
unlike MPA and NET-A (Africander et al. 2011b, and references therein), has been shown to elicit 
anti-mineralocorticoid activity, while NET-A, LNG and GES have all been shown to bind to estrogen 
receptor (ER)-α, but not ERβ (Louw-du Toit et al. 2017a). MPA, NET-A, LNG, GES, NES, NOMAC 
and DRSP have all been shown to bind the androgen receptor (AR) (Africander et al. 2014; Louw-
du Toit et al. 2017a), which is the most widely expressed steroid receptor in breast cancer (Søreide 
et al., 1992; Garay and Park, 2012). However, while MPA, NET-A, LNG and GES display 
androgenic properties similar to the natural androgen 5α-dihydrotestosterone (DHT), NES, NOMAC 
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and DRSP display anti-androgenic properties similar to P4 (Africander et al. 2014; Louw-du Toit et 
al. 2017a).  
 
Multiple steroid receptors have been implicated in breast cancer biology, and these receptors often 
influence each other’s activity (reviewed in (Sikora 2016)). For example, the DHT-activated AR has 
been shown to inhibit ERα transcriptional activity, resulting in the inhibition of ER-positive breast 
cancer cell growth (Peters et al., 2009). In addition, the androgen-activated AR also inhibited breast 
cancer cell growth by increasing ERβ expression (Rizza et al., 2014). Considering that progestins 
like MPA, NET-A and LNG display similar androgenic properties as the natural androgen DHT 
(Africander et al. 2014; Louw-du Toit et al. 2017a), the question arises whether these progestins 
would also increase ERβ expression. Considering the wide-spread expression of the AR in breast 
cancer tumours and its association with a favorable prognosis and lower tumour grade in ER-positive 
breast cancer (Castellano et al., 2010; Hu et al., 2011; Park et al., 2011; Garay and Park, 2012; Tsang 
et al., 2014), therapies targeting AR signaling are actively being researched (reviewed in (Rahim & 
O’Regan 2017)). Thus, if progestins displaying androgenic activity elicit similar effects as the 
androgens in breast cancer, these synthetic compounds may in fact be beneficial rather than harmful 
in breast cancer. Indeed, MPA has previously been used to treat breast cancer (Blossey et al., 1984; 
Etienne et al., 1992; Yamashita et al., 1996), and the AR was required for these effects (Birrell et al. 
1995a). It is therefore crucial to elucidate the mechanism of action of progestins binding to the AR, 
in order to understand how these ligands may either contribute to the development and progression 
of breast cancer or possibly be used in breast cancer treatment. 
 
1.2 Progestins 
It is well-known that the natural progestogen, P4, has a relatively short biological half-life due to its 
rapid metabolism in vivo (Speroff and Darney, 1996). Synthetic progestogens, known as progestins, 
were thus designed to mimic the biological actions of P4 via the PR, and have a longer half-life and 
higher bioavailability than P4 (Sitruk-Ware, 2006; Stanczyk et al., 2013). Progestins were designed 
in four consecutive generations, with the fourth generation progestins designed to be more selective 
in terms of binding to the PR (Stanczyk 2003; Schindler et al. 2003; Sitruk-Ware 2006; Africander 
et al. 2011a; Stanczyk et al. 2013). Numerous progestins with distinctly different structures are 
clinically available. Examples of the first generation progestins include MPA, and NET-EN or NET-
A.  NET-EN is a derivative of NET used in contraception, while NET-A is the acetate ester of NET 
used in both oral contraception and menopausal HT (Schindler et al., 2003; Stanczyk, 2003; Sitruk-
Ware and Plu-Bureau, 2004). Both NET-EN and NET-A are prodrugs that are metabolically 
converted to the biologically active NET (Stanczyk and Roy, 1990; Garza-Flores et al., 1991; Kuhnz 
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et al., 1997). LNG, a derivative of NET, forms part of the second generation progestins, while GES, 
a derivative of LNG, forms part of the third generation progestins (Sitruk-Ware, 2006). The fourth 
and newest generation include progestins like NES, NOMAC and DRSP (Schindler et al., 2003; 
Stanczyk, 2003; Stanczyk et al., 2013). Progestins are derived from different parent compounds like 
P4 and testosterone (T) (Figure 1.1). Those that are structurally related to P4 include either 17α-
hydroxyprogesterone derivatives like MPA, or 19-norprogesterone derivatives like NES and 
NOMAC.  Progestins that are structurally related to T include 19-nortestosterone derivatives like 
NET-EN/NET-A, LNG and GES (Schindler et al., 2003; Stanczyk, 2003; Stanczyk et al., 2013). 
DRSP is the only progestin that is derived from the MR antagonist, spironolactone (Krattenmacher, 
2000).   
 
 Many progestins elicit their biological activities via binding to not only the PR, but also other steroid 
receptors such as the glucocorticoid receptor (GR), mineralocorticoid receptor (MR), androgen 
receptor (AR), and estrogen receptor alpha (ERα) (Koubovec et al. 2005; Sitruk-Ware 2006; Stanczyk 
et al. 2013; Africander et al. 2013; Africander et al. 2014; Louw-du Toit et al. 2017a). Moreover, 
these progestins often elicit differential effects when binding to these receptors. For example, MPA 
and GES, unlike NET-A and LNG, have been shown to display glucocorticoid-like activity 
(Africander et al. 2011b; Stanczyk et al. 2013; Koubovec et al. 2005). In addition, DRSP displays 
potent anti-mineralocorticoid activity, while MPA and NET-A do not (Krattenmacher 2000; 
Africander et al. 2011a; Africander et al. 2013). MPA, NET-A, LNG and GES can also display 
androgenic properties, while NES, NOMAC and DRSP display anti-androgenic properties 
(Africander et al. 2014; Louw-du Toit et al. 2017a). Lastly, NET-A, LNG and GES, but not MPA, 
NES, NOMAC and DRSP, have been reported to display partial estrogenic activity by binding to 
estrogen receptor ERα, but not ERβ (Louw-du Toit et al. 2017a).   
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Figure 1.1. Structures of selected progestins from four consecutive generations. Progestins structurally 
related to (A) progesterone (P4) include either 17α-hydroxyprogesterone derivatives like the 1st generation 
progestin medroxyprogesterone acetate (MPA), or 19-norprogesterone derivatives like the 4th generation 
progestins nestorone (NES) and nomegesterol acetate (NOMAC). The spironolactone derived progestin, 
drospirenone (DRSP), also forms part of the 4th generation progestins. Progestins structurally related to (B) 
testosterone (T) include the 1st generation progestins norethisterone enanthate (NET-EN)/norethisterone 
acetate (NET-A), 2nd generation progestins like levonorgestrel (LNG), and 3rd generation progestins like 
Gestodene (GES) are also structurally related to T. The structures used in this figure are from (Louw-du Toit 
et al. 2017b). 
 
1.2.1 Therapeutic applications 
Progestins have a wide range of therapeutic applications, such as the treatment of PCOS (Archer and 
Chang, 2004; Guido et al., 2004; Ehrmann, 2005), endometriosis (Harrison and Barry-Kinsella, 2000; 
Irahara et al., 2001; Vercellini et al., 2003) and menstrual disorders such as dysfunctional and 
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irregular uterine bleeding, menorrhagia (heavy menstruation) and dysmenorrhea (painful 
menstruation) (Williams and Creighton, 2012). In addition, some progestins are used to treat skin 
disorders such as acne vulgaris and hirsutism (Rosen et al., 2003; Archer and Chang, 2004; Guido et 
al., 2004; Batukan and Muderris, 2006; Krunic et al., 2008; Olutunmbi et al., 2008). Interestingly, at 
high doses of 500 – 1500 mg/day, some progestins like MPA have been used in cancer therapy 
(Blossey et al., 1984; Etienne et al., 1992; Yamashita et al., 1996). However, these compounds are 
most commonly used in contraception and menopausal HT (Kuhl, 2005), which will be discussed in 
the following sections. 
 
 1.2.1.1 Contraception 
Progestins prevent pregnancy by inhibiting ovulation, causing endometrial atrophy and altering the 
cervical mucus to prevent sperm penetration and fertilization (Greydanus et al., 2001; Sitruk-Ware, 
2006; Sitruk-Ware and Nath, 2010). These compounds are either administered in combination with 
an estrogen, such as E2 or ethinyl estradiol (EE), or used as progestin-only contraceptive agents 
(Solter, 1999; Greydanus et al., 2001; Erkkola and Landgren, 2005). Contraceptives are available in 
various doses and can be administered via different routes. For example, it can either be administered 
orally, via intramuscular injections, transdermal gels, patches or sprays, through implants or 
intrauterine devices (Toppozada et al., 1983; Brache et al., 2000; Greydanus et al., 2001; Sitruk-
Ware, 2006; Sitruk-Ware and Nath, 2010; Sitruk-Ware et al., 2013). 
 
The first generation progestins, MPA and NET-EN, are the most commonly used injectable 
contraceptives amongst females in South Africa (Draper et al., 2006). While MPA, also referred to 
as Depo-Provera®, is administered intramuscularly at a dose of 150 mg every three months, NET-
EN (Noristerat®) is administered at a 200 mg dose every two months (Toppozada et al., 1983; Draper 
et al., 2006). NET-EN is hydrolyzed to NET and other metabolites, which together have contraceptive 
action (Stanczyk and Roy, 1990; Garza-Flores et al., 1991; Kuhnz et al., 1997). In contrast, MPA 
itself is the active contraceptive agent (Mishell, 1996). The second generation progestin, LNG, is 
frequently encountered in the Mirena® intrauterine system, which delivers 12–20 µg LNG per day 
(Backman et al., 2004; Fraser, 2013), but can also be used as an emergency oral contraceptive within 
24 hours before, or up to 120 hours after, unprotected sexual intercourse (Cheng et al., 2008). LNG 
is also available in a vaginal gel that can be applied before sexual intercourse to induce ovary 
dysfunction (Brache et al., 2007; Massai et al., 2007). Other progestins like the third generation 
progestin, GES, is commonly used in transdermal patches containing 1.9 mg GES in combination 
with 0.9 mg EE (Heger-Mahn et al., 2004). However, it has also been used in combined oral 
contraceptive pills such as Minulet®, which contains 0.075 mg GES in combination with 0.03 mg 
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EE (Kirkman et al., 1994). Although not active as an oral contraceptive (Schindler et al., 2003), NES 
is the most potent anti-ovulatory compound amongst the progestins when parenterally administered 
(Kumar et al., 2000; Nath and Sitruk-Ware, 2009). NES can be administered either alone (75–100 
µg/day) or in combination with EE (150 µg NES + 15 µg EE) in a sustained-release vaginal ring 
(Sitruk-Ware et al., 2003). The fourth generation progestin, NOMAC is administered either in 
combination with E2 in oral contraceptive agents such as Zoely® (2.5 mg NOMAC + 1.5 mg E2) 
(Burke, 2013), or alone in subdermal implants (Uniplant®) (Coutinho et al., 1996; Devoto et al., 
1997). DRSP, is commonly used as a combined oral contraceptive in South Africa (Steyn and Kluge, 
2010), and contains 3 mg DRSP in combination with either a low dose (20 µg) EE (Yaz®) (Tan and 
Ediriweera, 2009) or a higher dose of 30 µg (Yasmin®) (Parsey and Pong, 2000). Interestingly, 
progestins have also been investigated in male contraception (Kamischke et al., 2000, 2001; 
Nieschlag et al., 2003; Gu et al., 2004; Ilani et al., 2012; Sitruk-Ware et al., 2013). Here, progestins 
like MPA and NET-EN are administered in combination with testosterone, to reduce the secretion of 
gonadotropins and suppress sperm production (Kamischke et al., 2000, 2001; Nieschlag et al., 2003; 
Gu et al., 2004; Ilani et al., 2012; Sitruk-Ware et al., 2013). 
 
 1.2.1.2 Hormone therapy (HT) 
HT is used by millions of women to alleviate the symptoms associated with menopausal transition 
caused by a decline in estrogen levels (Greendale et al., 1999; Hickey et al., 2005). These symptoms 
include hot flushes, night sweats, bone loss, as well as vaginal atrophy and dryness (Greendale et al., 
1999; Hickey et al., 2005). HT is administered as either estrogen alone to women who have had a 
hysterectomy, or estrogen in combination with a progestin to women with an intact uterus (Greendale 
et al., 1999; Hickey et al., 2012). The progestin component in HT serves to oppose the proliferative 
effects of estrogen on the endometrium, thereby preventing endometrial cancer (Whitehead et al., 
1979; Greendale et al., 1999; Hickey et al., 2005). Progestins can be administered with estrogens like 
E2, EE, conjugated equine estrogen (CEE) or E2-valerate (E2V) (Mueck and Römer, 2018). Although 
the most common route of menopausal HT delivery is oral (Stanczyk et al., 2013), it can also be 
delivered via intrauterine systems, transdermal patches, gels or sprays (Kuhl, 2005; Sitruk-Ware, 
2007; Mueck and Römer, 2018).  
 
MPA is commercially available as Prempro®, which contains MPA (1.5-5 mg) plus conjugated 
equine estrogen (CEE) (0.3-0.625 mg) (Prempro® package insert, Wyeth Pharmaceuticals Inc.), or 
the progestin-only Provera® (2.5-10 mg) (Provera® package insert, Pfizer Inc.) that is orally 
administered in combination with an estrogen-only HT (Nachtigall et al., 1979). Peak serum 
concentrations of MPA have been reported to range between 0.2 and 13 nM (Hiroi et al., 1975). NET-
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A (0.1–1 mg) can be administered orally in combination with either EE (0.0025-0.01 mg), available 
as FemHRT® (FemHRT® package insert, Warner Chicott Inc.), or E2 (0.5–1 mg), available as either 
Avtivella® (Activella package insert, Movo Nordisk Inc.) or Mimvey® (Mimvey® package insert, 
Teva Pharmaceuticals Inc.). Alternatively, NET-A is also used in transdermal patches 
(Combipatch®) containing a fixed dose of E2 (0.05 mg) in combination with NET-A (0.14–0.25 mg). 
Peak serum concentrations of NET-A in HT have been reported to be between 3.64-17.7 nM (Jinteli 
package insert, Teva Pharmaceuticals, USA). Although LNG (0.015 mg) can be administered via a 
transdermal patch containing E2 (0.045 mg) (Climara Pro®) (Shulman et al., 2002), it is frequently 
administered via an intrauterine device, such as the Mirena®, at lower doses than those used in 
contraception, and combined with either oral or transdermal estrogens like E2 or E2V (Suhonen et al., 
1997; Varila et al., 2001; Raudaskoski et al., 2002; Sturdee et al., 2004; Varma et al., 2006). Peak 
serum concentrations of LNG in HT have been reported to be within the range of 0.35–1.53 nM 
(Mirena® package insert, Bayer Health Care Pharmaceuticals Inc.). The fourth generation DRSP is 
commonly administered as an oral contraceptive pill that contains E2 (1 mg E2 plus 1–3 mg DRSP), 
and is commercially available as Angeliq® (Archer et al., 2005; Genazzani et al., 2013; Perkins et 
al., 2018). Interestingly, peak serum concentrations of DRSP are reported to be higher (5.45–231.93 
nM) than that of MPA, NET-A and LNG (Angeliq® package insert, Bayer Pharmaceuticals, Europe).  
 
 1.2.2 Side-effects 
A number of side-effects have been associated with the clinical use of progestins, some more severe 
than others. In contrast, no major side-effects have been associated with the clinical use of P4 (Writing 
group for the PEPI trial 1995; Fournier et al. 2008). Some of the side-effects considered to be less 
severe include headaches, nausea, mood changes, insomnia, reduced libido, breast tenderness, as well 
as irregular bleeding (Greydanus et al., 2001; Sitruk-Ware, 2004, 2006; Erkkola and Landgren, 2005; 
Williams and Creighton, 2012). On the other hand, more severe side-effects include an increased risk 
of cardiovascular disease, VTE, genital tract infections, as well as ovarian and breast cancer (Writing 
group for the PEPI trial 1995; Rossouw et al. 2002; Beral et al. 2003; Gomes & Deitcher 2004; 
Fournier et al. 2008; Polis et al. 2016). In terms of progestins and the link to increased breast cancer, 
studies have shown that the postmenopausal use of MPA (Rossouw et al., 2002; Beral et al., 2003; 
Fournier et al., 2008) , NET, LNG and NOMAC (Beral et al., 2003; Fournier et al., 2008) is associated 
with an increased risk of invasive breast cancer. However, the association between many other 
progestins and increased breast cancer risk is unknown.  
 
Most side-effects associated with the use of progestins are thought to be due to their cross-reactivity 
with steroid receptors other than the PR (Hapgood et al. 2004; Africander et al. 2011a; Stanczyk et 
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al. 2013). For example, the use of MPA, but not NET, has been shown to increase inflammation in 
the female genital tract due to its glucocorticoid activity . Increased inflammation in the genital tract 
has previously been shown to increase a woman’s susceptibility to genital tract infections such as 
gonorrhea, Chlamydia, herpes simplex virus type (HSV)-2 and human immunodeficiency virus 
(HIV)-1 (Mostad et al., 2000; Morrison et al., 2004, 2010). Another side-effect associated with the 
glucocorticoid-like activity of MPA is decreased bone mineral density in adolescent women (Kass-
Wolff, 2001; Cromer et al., 2004; Williams and Creighton, 2012). However, these effects are reversed 
when usage is terminated (Cundy et al., 1994).  
 
Progestins from all generations have been associated with an increased risk of VTE, a condition 
referring to the formation of blood clots, which could subsequently lead to a stroke or pulmonary 
embolism (Odlind et al., 2002; Rossouw et al., 2002; Warren, 2004; Lidegaard et al., 2009, 2012; 
Van Hylckama Vlieg et al., 2009; Manzoli et al., 2012; Sidney et al., 2013). Interestingly, the fourth 
generation progestin, DRSP, is generally considered to be associated with a greater VTE risk than the 
third generation progestin, GES, which has a greater risk than first generation NET or second 
generation LNG (Kemmeren et al., 2001; Odlind et al., 2002; Van Vliet et al., 2004; Lidegaard et al., 
2009; Van Hylckama Vlieg et al., 2009).  
 
The lack of anti-mineralocorticoid activity of progestins like NET-A and LNG (Oelkers, 2005; 
Stanczyk et al., 2013) has been shown to lead to the elevation of blood pressure in postmenopausal 
women (reviewed in (Africander et al. 2011a)). In contrast, the fourth generation progestin, DRSP, 
which is known to display potent anti-mineralocorticoid activity, has been reported to elicit 
antihypertensive and cardio protective effects (reviewed in Oelkers, 2005). The androgenic activity 
of progestins like MPA, NET-A and LNG, has been shown to counteract the beneficial effects of 
estrogen on high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol 
(LDL-C) in postmenopausal women using HT (Crook et al. 1992; Writing Group for the PEPI trial, 
1995). Thus, the use of progestins displaying androgenic activity could be an arterial risk factor 
causing cardiovascular disease (reviewed in Sitruk-Ware, 2000). In contrast, detrimental side-effects 
on lipoprotein levels have not been observed with progestins like NOMAC and DRSP, which display 
anti-androgenic activity (Ottosson et al. 1985; Saarikoski et al. 1990; Basdevant et al. 1991; Writing 
Group for the PEPI trial, 1995; Hulley et al. 1998; Sitruk-Ware 2000; Taneepanichskul & Phupong 
2007; Ågren et al. 2011; Sitruk-Ware & Nath 2013).  
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1.3 Progestogens and breast cancer 
 
 1.3.1 Clinical and epidemiological studies 
Breast cancer is the common cancer among women worldwide, and is the main cause of cancer-
related deaths in women living in developed countries (Ferlay et al., 2015; Torre et al., 2015; Siegel 
et al., 2016). While several investigations prior to 2002 have associated the use of progestins in HT 
with an increased risk of invasive breast cancer (Writing group for the PEPI trial 1995; Magnusson 
et al. 1999; Persson et al. 1999; Schairer et al. 2000; Ross et al. 2000), it was the findings of the 
Women’s Health Initiative (WHI) trial (Rossouw et al., 2002) that raised major concerns and 
confusion about the safety of HT. The WHI trial consisted of an estrogen-only arm where 
postmenopausal women who have undergone a hysterectomy were treated with CEE, and an 
estrogen-progestin arm, where postmenopausal women with an intact uterus were treated with CEE 
plus MPA. The latter arm was prematurely terminated in 2002 due to the incidence of increased 
invasive breast cancer and cardiovascular events, while the estrogen-only arm was terminated two 
years later due to increased risk of VTE and stroke, but not breast cancer risk. These results indicated 
that the progestin component in HT was responsible for the increased breast cancer risk. However, 
careful analysis of the trial data indicated that this increased risk of invasive breast cancer was only 
in women who had used HT for a prolonged period of time (5-10 years) (Sitruk-Ware and Plu-Bureau, 
2004; Warren, 2004; Hickey et al., 2005). Women who were first-time users of CEE plus MPA did 
not show this risk of invasive breast cancer (Sitruk-Ware and Plu-Bureau, 2004).  
 
Increased breast cancer risk with the clinical use of progestins was, however, also shown by the 
Million Women Study (MWS) (Beral et al., 2003). This study investigated multiple progestins and 
included women between the ages of 50 and 64 who had never used HT (never-users), women who 
were using HT at recruitment (current-users), and women who had previously used HT (past-users). 
MPA, NET and LNG increased risk in both current and past users, but not in never-users. 
Interestingly, there were no differences in breast cancer risk between the specific progestins 
investigated. In contrast to the WHI trial, the MWS showed that the estrogen-only arm also increased 
breast cancer risk, but that the risk was significantly less than the estrogen-progestin arm. 
Interestingly, results indicated a risk of breast cancer in overall HT users, in comparison to non-users, 
after only one year of HT usage (Beral et al. 2003; Sitruk-Ware & Plu-Bureau 2004), suggesting that 
HT activates existing tumours rather than inducing the formation of new tumours (Sitruk-Ware and 
Plu-Bureau, 2004; Hickey et al., 2005). The French E3N cohort also showed that both estrogen-only 
and estrogen-progestin combination HT increased breast cancer risk in postmenopausal women 
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(Fournier et al., 2008; Clavel-Chapelon, 2015). However, the use of estrogen-progestin combination 
HT was again associated with a larger risk than estrogen-only treatment.  The progestins used in this 
study were MPA, NET-A and NOMAC, and no significant difference in breast cancer risk was 
observed between these progestins. Furthermore, results from this study showed that the risk of breast 
cancer increases with the duration of estrogen-progestin combination HT usage, even after as little as 
two years. In contrast to the above-mentioned studies , the Heart and Estrogen/Progestin Replacement 
Study (HERS) I and HERS II (Hulley et al., 2002) studies reported no increased breast cancer risk 
with either the use of CEE or CEE plus MPA. Similarly, several studies have reported no increased 
breast cancer risk associated with the menopausal HT use of oral E2-only or E2 plus NET-A (Obel et 
al., 1993; Tierney et al., 2009; Schierbeck et al., 2012). Moreover, is noteworthy that the French E3N 
study reported that the use of P4 was not associated with an increased breast cancer risk (Fournier et 
al., 2008). Similarly, results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial 
also reported that the use of oral micronized P4 in combination with CEE does not increase breast 
cancer risk (Writing group for the PEPI trial 1995). In contrast, the Early Versus Late Intervention 
Trial (ELITE) showed that the use of a P4 vaginal gel in combination with oral E2 increased breast 
cancer risk (reviewed in (Marjoribanks et al. 2017)). Similarly, results from the Kronos Early 
Estrogen Prevention Study (KEEPS) showed that the use of micronized P4 in combination with E2 
also increased breast cancer risk (reviewed in (Marjoribanks et al. 2017)). 
 
Contradictory findings have also been reported for the use of progestins in contraception (Lee et al., 
1987; Althuis et al., 2003; Hunter et al., 2010; Li et al., 2012; Beaber et al., 2014). For example, 
some studies suggest that the contraceptive use of MPA as an intramuscular injection does not 
increase breast cancer risk (Kaunitz, 1996; Dills and Schreiman, 2003; Bakry et al., 2008), while 
others have shown that it increased breast cancer risk in women between 20 and 58 years of age (Lee 
et al., 1987; Li et al., 2012). Similarly, the use of NET in combined oral contraceptives has been 
associated with an increased breast cancer risk (Althuis et al., 2003), while another study reported no 
increase (Hunter et al., 2010). Studies investigating the use of the second generation progestin, LNG, 
in combined oral contraception also reported an increased breast cancer risk (Althuis et al., 2003; 
Hunter et al., 2010). A recent population-based case-control study also showed that the use of NET, 
LNG and DRSP in combined oral contraceptives, increased breast cancer risk (Beaber et al., 2014). 
Taken together, the evidence in the literature indicates that the role of progestins in breast cancer 
development is not straightforward. Further investigation is therefore required to determine the 
conditions under which progestins (in contraceptive or menopausal HT use) facilitate the 
development of breast cancer in women. Moreover, as there are numerous progestins with different 
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structures available for clinical use, it is important that individual progestins are assessed in terms of 
their risk profile. 
 
1.3.2 Experimental studies 
Numerous studies have investigated the effects of progestins on proliferation of normal and cancerous 
breast cell lines, but results are often conflicting (Jeng and Jordan, 1991; Van Der Burg et al., 1992; 
Jeng et al., 1992; Catherino et al., 1993; Botella et al., 1994; Kalkhoven et al., 1994; Schoonen et al., 
1995a, 1995b; Franke and Vermes, 2003; Krämer et al., 2006; Ruan et al., 2012). A study by Krämer 
et al. (2006) showed that MPA increased the proliferation of growth factor-induced normal MCF10A 
breast cells, while P4, NET and LNG had no effect. In the malignant HCC1500 breast cells, however, 
NET, LNG and GES enhanced the proliferation of growth factor-treated cells, while MPA had an 
inhibitory effect, and P4 no significant effect (Krämer et al., 2006). In agreement with this study, 
studies have shown that NET, LNG and GES increase proliferation of the human MCF-7 and T47D 
breast cancer cell lines (Jeng and Jordan, 1991; Jeng et al., 1992; Van Der Burg et al., 1992; Catherino 
et al., 1993; Kalkhoven et al., 1994; Schoonen et al., 1995a; Franke and Vermes, 2003; Ruan et al., 
2012). (Schoonen et al., 1995b). In contrast to these studies,  a study by Botella et al. (1994) showed 
that MPA and NET decreased proliferation of T47D breast cancer cells in a dose-dependent manner. 
Numerous other studies have however showed that MPA has no effect on the proliferation of MCF-
7 cells (Jeng and Jordan, 1991; Jeng et al., 1992; Van Der Burg et al., 1992; Catherino et al., 1993; 
Schoonen et al., 1995a; Ruan et al., 2012). In terms of the fourth generation progestins, DRSP has 
been shown to increase proliferation of MCF-7 cells, while NOMAC had no effect (Ruan et al., 2012). 
In contrast, NOMAC has previously been shown to decrease proliferation of T47D breast cancer cells 
in a dose-dependent manner (Botella et al., 1994). Studies investigating the effects of P4 on breast 
cancer cell proliferation are also conflicting. For example, P4 has been shown to exert anti-
proliferative (Formby and Wiley, 1998; Wiebe et al., 2000) and proliferative (Schoonen et al., 1995b; 
Franke and Vermes, 2003; Liang et al., 2006) effects in the MCF-7 and T47D cells, but also no effect 
on MCF-7 breast cancer cell proliferation (Schoonen et al., 1995a).  
 
Studies investigating the effects of progestins on other hallmarks of breast cancer are limited. 
However, it has been shown that MPA elicits anti-apoptotic effects in the MCF-7, T47D and H466B 
breast cancer cell lines (Ory et al., 2001; Franke and Vermes, 2003). Similarly, NET-A has been 
shown to inhibit apoptosis in the MCF-7 breast cancer cell line (Franke and Vermes, 2003). However, 
the effect of P4 on apoptosis is contradictory. For example, at high concentrations (10 µM) P4 is 
reported to elicit pro-apoptotic effects in MCF-7 (Franke and Vermes, 2003) and T47D cells (Formby 
and Wiley, 1998, 1999), while a lower concentration (100 nM) was shown to be anti-apoptotic in 
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T47D cells (Moore et al., 2006). Furthermore, MPA, NES, DRSP and P4, alone and in combination 
with E2, enhanced migration and invasion of T47D breast cancer cells (Fu et al., 2008). However, 
MPA was reported to promote migration and invasion to a larger extent than NES, DRSP and P4. 
Furthermore, P4, MPA, NET and LNG have been shown to increase angiogenesis, which promotes 
tumour growth and metastasis, in T47D cells via the upregulation of vascular endothelial growth 
factor (VEGF) mRNA expression (Hyder et al., 1998; Mirkin et al., 2005). P4, MPA and NET also 
increased the protein expression of VEGF in T47D cells (Hyder et al., 2001), while at least one study 
has shown that these progestins have no effect on VEGF protein expression in MCF-7, MDA-MB-
231 and ZR-75 human breast cancer cells (Hyder et al., 1998). Considering the above, it is clear that 
results from experimental studies investigating the effects of progestins on the hallmarks of breast 
cancer are not clear and warrants further investigation. Although in vitro studies cannot replace 
clinical studies, these experiments are useful in order to directly compare activities of different 
progestins in the same model systems, which may lay the foundation for future clinical studies. 
 
1.4 Role of progestogens and steroid receptors in breast cancer biology 
 
 1.4.1 General mechanism of action of steroid receptors 
Progestogens elicit their progestogenic effects by binding to the progesterone receptor (PR) (Hapgood 
et al. 2004; Sitruk-Ware 2006; Stanczyk et al. 2013). The PR, together with the estrogen receptor 
(ER), androgen receptor (AR), glucocorticoid receptor (GR), and mineralocorticoid receptor (MR), 
comprise the steroid receptor family. These receptors are ligand-activated transcription factors that 
all share a high degree of structural similarity (Figure 1.2) (reviewed in (Griekspoor et al. 2007)). 
Although steroid receptors function via similar mechanisms, their target genes and target tissues may 
differ (McKenna and O’Malley, 2002). In general, these steroid receptors all contain a highly variable 
NH2-terminal domain (NTD), a well conserved DNA-binding domain (DBD) and a moderately 
conserved ligand-binding domain (LBD) located at the COOH-terminal (Mangelsdorf et al., 1995). 
While the LBD is involved in the binding of ligand to the steroid receptor, the DBD allows for binding 
to specific DNA sequences in target genes, steroid receptor dimerization, and interactions with co-
factors  (reviewed in (Griekspoor et al. 2007)). Furthermore, steroid receptors harbor two major 
transcriptional activation domains, namely activation function-1 (AF-1), which is constitutively 
active and located in the NTD, and activation function-2 (AF-2), which is a ligand-dependent domain 
located in the LBD  (Griekspoor et al., 2007). The AF-2 domain interacts with co-activators to induce 
the transcriptional activity of the receptor (Aagaard et al., 2011), while the AF-1 domain allows for 
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optimal transcriptional activity of the steroid receptor (Lavery and McEwan, 2005; Aagaard et al., 
2011).  
 
In the absence of hormone, the AR, GR and MR predominantly reside in the cytoplasm, while the ER 
subtypes and PR-A isoform are found predominantly in the nucleus (Li, 2005; Griekspoor et al., 
2007). PR-B is distributed uniformly between the cytoplasm and the nucleus (Griekspoor et al., 
2007). When a ligand binds to a steroid receptor, a conformational change is induced in the receptor, 
allowing it to dissociate from chaperone proteins, such as heat-shock protein (Hsp)90 and Hsp70, 
phosphoprotein p23, and immunophillin p59 (Pratt and Toft, 1997; Griekspoor et al., 2007). The 
ligand-steroid receptor complex subsequently translocates to the nucleus, where it binds to specific 
regulatory elements within the promoter region of target genes to activate transcription 
(transactivation) (reviewed in (Huang et al. 2010; Africander et al. 2011a)). Transcription can also 
be repressed (transrepression) via the liganded steroid receptor interacting with DNA-bound 
transcription factors (reviewed in (Huang et al. 2010; Africander et al. 2011a)).  
 
For transactivation of target genes, it is generally accepted that the ligand-bound steroid receptor 
binds as a dimer to specific palindromic DNA sequences known as steroid response elements (SREs) 
(reviewed in (Griekspoor et al. 2007)). Due to the high level of conservation in the DBD of steroid 
receptors (reviewed in (Africander et al. 2011a)), most steroid receptors can bind the same SRE. For 
example, while the PR binds to progesterone response elements (PREs), this consensus DNA 
sequence can also be bound by other steroid receptors like the AR, MR and GR. In this case, the SRE 
is then called the androgen response element (ARE), mineralocorticoid response element (MRE) and 
glucocorticoid response element (GRE), respectively. In contrast to the AR, MR and GR, the ER is 
unique in that it binds specifically to estrogen response elements (EREs) (Klinge, 2001). On the other 
hand, the primary mechanism for transrepression involves an indirect binding of the ligand-bound 
steroid receptor to DNA-bound transcription factors such as nuclear factor-kappa B (NFκB) or 
activator protein-1 (AP-1) (McEwan et al., 1997; Webster and Cidlowski, 1999). Although not 
described here, it is noteworthy that steroid hormones can also elicit their effects via rapid non-
genomic mechanisms. These mechanisms may involve membrane steroid receptors or the activation 
of other signaling pathways, like the c-Src/Ras/mitogen-activated protein kinase (MAPK) or 
phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathways (Stellato, 2004; Boonyaratanakomkit 
et al., 2007; Wieman, 2007; Zhu et al., 2008; Grossmann and Gekle, 2009). 
 
All the steroid receptors have been implicated in breast cancer biology, and often influence each 
other’s activity   (reviewed in (Sikora 2016; Perkins et al. 2018)). As the PR, ER and AR are the best 
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studied in breast cancer, and knowing that some progestins can act via these receptors, the following 
sections will briefly describe the role of progestins and/or the PR, ER and AR on the hallmarks of 
breast cancer.  
 
  
Figure 1.2. A schematic illustration of the general structural organization of the functional domains of 
steroid receptors. Steroid receptors contain a variable NH2-terminal domain (NTD), denoted by A/B, with a 
constitutively active activation function-1 (AF-1) transactivation domain. The highly conserved DNA-binding 
domain (DBD) is denoted by C, while the hinge region is denoted by D. The relatively conserved ligand-
binding domain (LBD), which contains a ligand-dependent AF-2 transactivation domain, is located at the 
COOH-terminal of the receptor (E). The additional AF-3 domain in PR-B is also shown. ERα contains an 
additional domain at the COOH-terminal (F), of which the function is not known. The relevant motifs indicated 
in the AF-1 domain of the AR are crucial for the N/C interaction.  
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 1.4.2 Progestogens and the PR isoforms 
The biological effects of progesterone are mediated by the PR (Grimm et al., 2016), which exists as 
three distinct isoforms (Figure 1.2), namely PR-A (94 kDa), PR-B (110 kDa) and PR-C (60 kDa), 
transcribed from different promoters of a single gene (Kastner et al., 1990; Wei and Gonzalez-Aller, 
1990; Rekawiecki et al., 2011). PR-C, however, is not functional as it lacks a significant part of the 
DBD, which thus prevents DNA binding and transcription of target genes (Samalecos and Gellersen, 
2008; Daniel et al., 2011; Rekawiecki et al., 2011; Abdel-Hafiz and Horwitz, 2014). PR-B, but not 
PR-A, contains an AF-3 domain in the NTD, which facilitates the binding of certain co-activators to 
PR-B (Giangrande et al., 2000; Graham and Clarke, 2002; Tung et al., 2006). Thus, PR-B is 
considered to be more transcriptionally active than PR-A in the presence of agonist (Kastner et al., 
1990; Edwards et al., 1995; Rekawiecki et al., 2011; Jacobsen and Horwitz, 2012). In the absence of 
ligand, however, PR-A is generally more transcriptionally active than PR-B (Jacobsen et al., 2002). 
While PR-A and PR-B can regulate the same genes, there are some genes that are regulated only by 
a specific isoform (Richer et al., 2002; Lanari et al., 2012). For example, only 25% of P4-regulated 
genes are regulated by both PR-A and PR-B, while nearly 65% are regulated only by PR-B and 4% 
are regulated only by PR-A (Richer et al., 2002; Lanari et al., 2012). It is thus not surprising that the 
biological roles of PR-B and PR-A have been shown to differ (Clarke and Sutherland, 1990; Conneely 
and Lydon, 2000; Conneely et al., 2000, 2003; Graham and Clarke, 2002; Mulac-Jericevic and 
Conneely, 2004; Diep et al., 2015). In breast cancer, for example, PR-B has been shown to mediate 
the P4-induced upregulation of genes that promote metastasis, while PR-A mediated the upregulation 
of anti-apoptotic genes by P4 in T47D breast cancer cells (Richer et al., 2002). PR-B was also required 
for P4-induced upregulation of VEGF protein expression, which promoted tumour growth and 
metastasis (Wu et al., 2004). Considering that the PR isoforms differ in their transcriptional activity, 
as well as their biological roles, it is concerning that the role of the PR in breast cancer is generally 
studied as a whole, without consideration of the role of the individual isoforms.  
 
PR-A and PR-B are expressed in equimolar ratios in the normal breast (Mote et al., 2002; Richer et 
al., 2002), while PR-A is often over-expressed in breast cancer (Graham et al., 1995; Bamberger et 
al., 2000; Ariga et al., 2001; Hopp et al., 2004). In fact, the ratio of PR-A to PR-B expression is an 
important determinant of breast cancer development and progression (Graham et al., 1995; Mote et 
al., 2002; Hopp et al., 2004; Cui, 2005). For example, breast tumours expressing more PR-A relative 
to PR-B have been shown to be more aggressive, and lead to a poor disease-free survival rate (Hopp 
et al., 2004). Considering that progestins are PR ligands (Sitruk-Ware, 2006), and that some 
progestins have been shown to increase breast cancer, the question that arises is whether their effects 
in breast cancer are via the PR. Although this is now a topic of ongoing research, most studies do not 
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discern between the role of the PR isoforms. However, a limited number of studies have investigated 
the role of the PR isoforms in mediating the effects of progestins on breast cancer hallmarks (Wu et 
al., 2004; Moore et al., 2006; Giulianelli et al., 2012; Bellance et al., 2013; Kariagina et al., 2013; 
Wargon et al., 2015). For example, MPA has been shown to increase proliferation of the T47D human 
breast cancer cell line by upregulating the expression of cyclin D1 via the PR (Giulianelli et al., 2012; 
Wargon et al., 2015). Wargon and co-workers in fact showed that PR-B was required for the 
proliferative effects of MPA in T47D cells (Wargon et al., 2015). Interestingly, ERα has also been 
shown to be required for the PR-B-mediated effects of MPA in T47D cells (Giulianelli et al., 2012). 
This study was one of the first to show crosstalk between the PR and ERα in breast cancer. 
Promegestone (R5020), a PR-specific progestin widely used as an experimental tool to investigate 
the role of the PR, elicited anti-apoptotic effects in the MCF-7 and MDA-MB-231 breast cancer cell 
lines (Moore et al., 2006). As the effects of R5020 were reversed by the antagonist, mifepristone 
(RU486), the authors suggested that the PR was involved in these anti-apoptotic effects (Moore et 
al., 2006). Although the role of the individual PR isoforms was not investigated by Moore et al. 
(2006), it has previously been shown that both PR-A and PR-B contributed to the R5020-induced 
increase in migration and invasion of MDA-MB-231 breast cancer cells (Bellance et al., 2013). In 
contrast to these findings, PR-B, but not PR-A, was required for the R5020-induced increase in 
invasion of the T47D breast cancer cell line (Kariagina et al., 2013). Similarly, it was shown that both 
PR isoforms, but mainly PR-B, was required for the MPA- and NET-induced increase in VEGF 
protein expression in T47D cells (Wu et al., 2004). Considering these contradictory findings, and the 
limited PR isoform-specific investigations, it is clear that more molecular studies are needed to 
directly compare PR isoform-specific effects of P4 and progestins on hallmarks of breast cancer. 
Furthermore, as the ratio of PR-A to PR-B expression is a determining factor in breast cancer 
development and progression (Graham et al., 1995; Mote et al., 2002; Hopp et al., 2004; Cui, 2005), 
it is important to investigate the influence of the ratio of PR-A to PR-B in progestogen effects on 
breast cancer.  
 
1.4.3 Estrogens and the estrogen receptor (ER) subtypes 
Estrogens are involved in the growth and differentiation of the breast and other sex organs of the 
female reproductive system (Gruber et al., 2002; Gouglet et al., 2005; Thomas and Potter, 2013). 
There are three types of estrogens which are produced in the female body, namely estrone (E1), 17β-
estradiol (E2) and estriol (E3) (Thomas and Potter, 2013; Samavat and Kurzer, 2015), with E2 being 
the most biologically active (Samavat and Kurzer, 2015). The biological effects of estrogens are 
mediated by the ER, which exists as two subtypes (Figure 1.2), ERα (66 kDa) and ERβ (56 kDa), 
transcribed from different genes (Menasce et al., 1993; Matthews and Gustafsson, 2003). ERα and 
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ERβ share a high degree of sequence identity (96%) within their DBD, which explains why these 
subtypes can bind to similar sites in target genes (Matthews and Gustafsson, 2003). However, the 
LBD of ERα and ERβ is moderately conserved with a sequence identity of 53%, which could explain 
their differences in ligand binding specificity (Mosselman et al., 1996; Pearce and Jordan, 2004).  
 
It is well-known that E2 and ERα are considered the main etiological factors in breast cancer (Vogel, 
2018). In fact, ERα is expressed in nearly 70% of all breast cancers (Jensen and Jordan, 2003; Pearce 
and Jordan, 2004; Conzen, 2008), and is crucial for the proliferative effects of E2 in breast cancer 
(Couse & Korach 1999; Brisken & O’Malley 2010). This was shown in an animal experiment where 
exposure of ERα-knockout mice to E2 did not result in the formation of breast cancer tumours (Couse 
& Korach 1999; Brisken & O’Malley 2010). The actions of the E2-bound ERα in breast cancer include 
dysregulation of the cell cycle and apoptotic pathway, which ultimately promotes tumorigenesis 
(Hartman et al., 2009). For example, the E2-bound ERα has been shown to upregulate cell cycle 
genes, such as c-myc, cyclin D1, and cyclin A2, as well as anti-apoptotic genes, such as Bcl-x (Altucci 
et al., 1996; Frasor et al., 2003; Helguero et al., 2005; Hartman et al., 2009; Welboren et al., 2009). 
In addition, pro-apoptotic genes, such as Bax, have been shown to be downregulated by E2 (Helguero 
et al., 2005). Moreover, E2 has also been shown to stimulate the invasive and metastatic potential of 
MCF-7 ERα-positive human breast cancer cells (Shafie and Liotta, 1980; Osborne et al., 1985; Cos 
et al., 1986). It is thus not surprising that current therapies for E2-dependent breast cancer either 
inhibit ERα activity or inhibit E2 synthesis (Lanari et al., 2012; Lim et al., 2016; Doan et al., 2017). 
These therapies include selective ER modulators (SERMs), such as tamoxifen, selective ER 
downregulators (SERDs), such as fulvestrant (ICI 182,780) and aromatase inhibitors (AIs) (Jordan, 
2007; Mirzaie et al., 2013; Nantasenamat et al., 2013; Akçay and Bayrak, 2014; Patani and Martin, 
2014). SERMs are ER antagonists that compete with E2 and modulate ER activity, while SERDSs 
are ER antagonists that induce ER degradation (reviewed in (Patel & Bihani 2018)).  
 
Immunohistochemical analysis has shown that both ERα and ERβ are expressed in the normal breast, 
with the expression of ERβ being higher than that of ERα (Clarke et al., 1997; Russo et al., 1999; 
Speirs et al., 2004). In breast cancer, the subtypes are co-expressed in approximately 59% of primary 
breast tumours (Murphy et al., 2003), but expression of ERα is higher than that of ERβ (Leygue et 
al., 1998; Roger et al., 2001; Murphy et al., 2003; Shaaban et al., 2003). While ERα promotes 
tumorigenesis, ERβ antagonizes ERα-mediated effects (Leygue et al., 1998; Dotzlaw et al., 1999; 
Speirs et al., 1999; Zhao et al., 2008). However, the role of ERβ in breast cancer is bi-faceted, as it 
mimics the proliferative effects of ERα in ER-negative breast cancer (Leygue et al., 1998; Dotzlaw 
et al., 1999; Speirs et al., 1999; Williams et al., 2008; Zhao et al., 2008; Hartman et al., 2009; Leygue 
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and Murphy, 2013). For example, ERβ has been shown to increase breast cancer cell growth by 
upregulating the expression of proliferative markers like Ki67 and cyclin A, and downregulating the 
expression of the tumour-suppressor gene, p21 (Moore et al., 1988; Hou et al., 2004; O’Neill et al., 
2004; Skliris et al., 2006; Fox et al., 2008). Furthermore, it has been shown that an increase in ERβ 
expression, by stably transfecting different amounts of ERβ, resulted in an increased rate of 
proliferation of the  ERα-negative MDA-MB-231 and MDA-MB-453 breast cancer cells (Tonetti et 
al., 2003; Hou et al., 2004). Thus, in contrast to the inhibitory role of ERβ in ERα-positive breast 
cancer, the role of ERβ in ERα-negative breast cancer is not considered favorable (Tonetti et al., 
2003; Hou et al., 2004; Leygue and Murphy, 2013).  
 
From the above, it is clear that the role of E2 and the ER subtypes in breast cancer is complex. An 
added complexity is the fact that crosstalk between ERα and the PR plays an important role in breast 
cancer pathogenesis (Giulianelli et al., 2012; Daniel et al., 2015; Mohammed et al., 2015; Singhal et 
al., 2016). For example, it has been shown that unliganded PR-B can modulate the transcriptional 
activity of ERα by forming ERα/PR-B complexes at the promoters of certain ER target genes (Daniel 
et al., 2015). This resulted in a more aggressive proliferative response upon E2 stimulation of the 
MCF-7 breast cancer cell line (Daniel et al., 2015). In contrast, the P4- and R5020-activated PR has 
been shown to redirect the chromatin binding of the E2-activated ERα to PR binding sites 
(Mohammed et al., 2015). This involved an association between the PR and ERα, and ultimately 
resulted in altered transcriptional activity of ERα and the inhibition of cell growth in both MCF-7 
BUS and T47D cell lines (Mohammed et al., 2015). A similar mechanism was subsequently reported 
in primary ERα- and PR-positive breast cancer tumours (Singhal et al., 2016). A very recent study 
highlighted the PR isoform-specific modulation of ERα transcriptional activity (Singhal et al., 2018). 
It showed that the inhibition of gene expression and ER chromatin binding in T47D breast cancer 
cells was greater in the presence of PR-A than PR-B (Singhal et al., 2018). Moreover, the study by 
Singhal and co-workers also showed that the repression of ERα transcriptional activity is greater 
when the PR is bound to antagonist, than when it is bound to (Singhal et al. 2018). Taken together, 
these results suggest that the interplay between ERα and the PR can be associated with either good 
or poor prognosis in breast cancer, and that the outcome may be determined by the absence or 
presence of PR ligands. However, as progestins like MPA, NET-A and LNG are associated with 
increased breast cancer, we would hypothesize that not all PR ligands would result in a good 
prognosis. Further investigations are thus required to elucidate the role of the interplay between ERα 
and the PR. Moreover, whether similar crosstalk exists between the PR and ERβ is not known. 
Understanding the role of ER-PR crosstalk in breast cancer, as well as whether this interplay is 
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responsible for the observed effects of progestins in breast cancer, may facilitate the design of new 
progestins that do not cause increased breast cancer.   
 
1.4.4 Androgens and the androgen receptor (AR) 
A number of studies have shown that androgens and the AR play important roles in breast cancer 
biology (reviewed in (Rahim & O’Regan 2017)). In the presence of a classical AR agonist, an 
interaction between the amino- and carboxyl-terminal of the AR, more commonly known as the N/C 
interaction, occurs (He et al., 1999, 2000; Kemppainen et al., 1999; Schaufele et al., 2005; Van Royen 
et al., 2007, 2012; Africander et al., 2014). This AR N/C interaction is mediated by the AF-1 domain 
of the NTD and the AF-2 domain of the LBD (He et al., 1999, 2000). More specifically, the 
subdomains of AF-1 that have been implicated in this interaction include the FXXLF motif (sequence 
23FQNLF27) and WXXLF motif (sequence 433WHTLF437) (Figure 1.2) (He et al., 2000).The AR N/C 
interaction promotes stabilization of the receptor and slows down the rate of ligand dissociation (He 
et al., 1999; Kemppainen et al., 1999). The fact that the AR N/C interaction is not induced by all AR 
agonists, indicates that the interaction is not imperative to render the AR transcriptionally active 
(Kemppainen et al., 1999; Africander et al., 2014). Interestingly, the AR N/C interaction can take 
place either within one molecule (intramolecular) or between two AR molecules (intermolecular) 
(Schaufele et al., 2005), and is lost upon DNA binding, subsequently allowing the interaction of co-
factors and basal transcription machinery (Van Royen et al., 2007, 2012). 
 
The AR is expressed in approximately 90% of all primary breast tumours (Søreide et al., 1992; Garay 
and Park, 2012). It is thus not surprising that AR-targeted breast cancer treatment is actively being 
investigated (reviewed in (Rahim & O’Regan 2017)). However, the precise role and prognostic effect 
of the AR in breast cancer is greatly dependent on whether ERα is expressed (Fioretti et al., 2014; 
Lim et al., 2014). While the AR has been associated with an anti-proliferative role and favorable 
prognosis in ERα-positive breast cancer (Castellano et al., 2010; Hu et al., 2011; Park et al., 2011; 
Tsang et al., 2014), it is associated with a poor prognosis when mimicking the proliferative effects of 
ERα in ERα-negative breast cancers (Robinson et al., 2011; Rahim and O’Regan, 2017). For 
example, it has been shown that the natural androgen DHT and the synthetic non-metabolizable 
androgen, methyltrienolone (R1881), increased proliferation of the ERα-negative MDA-MB-453 
breast cancer cell line, as well as  MDA-MB-453 xenografts via the AR (Doane et al., 2006; Cochrane 
et al., 2014; Narayanan et al., 2014). Moreover, the AR has been shown to elicit growth promoting 
effects in molecular apocrine breast cancer tumours, which are ERα-negative and HER2-positive (Ni 
et al., 2011). Anti-androgens, like bicalutamide and enzalutamide, are thus currently being 
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investigated as options for treatment of AR-positive triple negative breast cancer (TNBC) (reviewed 
in (Rahim & O’Regan 2017)). 
 
In ERα-positive breast cancer, however, the favorable prognosis of the AR may be due to the 
inhibition of ERα activity (Birrell et al. 1995b; Panet-Raymond et al. 2000; Greeve et al. 2004; Peters 
et al. 2009; Need et al. 2012; Perkins et al. 2018). At least two mechanisms have been reported for 
the inhibitory role of the AR in ER-positive breast cancer (Peters et al., 2009; Rizza et al., 2014). For 
example, the DHT-bound AR has been shown to compete with ERα for binding to EREs in ER target 
genes (Peters et al., 2009). Another study has shown that crosstalk between the AR and ERβ may 
also be involved in the inhibitory effect of the AR, as both DHT and the synthetic androgen, 
Mibolerone (Mib), increased ERβ mRNA and protein expression (Rizza et al., 2014). The mechanism 
for this increase in ERβ expression was due to the activated AR binding to an ARE in the ERβ gene 
promoter (Rizza et al., 2014). Moreover, this increase in ERβ expression ultimately resulted in the 
inhibition of breast cancer cell growth in both the MCF-7 and ZR-75 breast cancer cell lines (Rizza 
et al., 2014). However, this study did not investigate the effects on ERα expression. Considering that 
the ER subtypes have opposite effects in breast cancer cell proliferation, with ERα being the driver 
of breast cancer cell proliferation (Leygue et al., 1998; Dotzlaw et al., 1999; Speirs et al., 1999; Zhao 
et al., 2008), it is important that its expression also be investigated. It is noteworthy that clinical trials 
are currently investigating the use of selective AR modulators (SARMs) for the treatment of ERα-
positive breast cancer (reviewed in (Rahim & O’Regan 2017)). SARMs are AR agonists that activate 
the AR in a tissue-specific manner (Narayanan et al., 2018). Interestingly, MPA, which is a potent 
AR agonist (Africander et al. 2014; Louw-du Toit et al. 2017a), has been used in breast cancer 
treatment at doses higher than those found in menopausal HT (Birrell et al. 1995a; Carroll et al. 
2016). In fact, the effects of MPA as breast cancer therapy has been shown to require the AR at the 
molecular level (Birrell et al. 1995a). Furthermore, like DHT, MPA also inhibited ERα transcriptional 
activity via the AR in MDA-MB-231 breast cancer cells, albeit to different extents (Peters et al., 
2009). However, it has also been shown that the AR-mediated effects of MPA disrupts the normal 
signaling of androgens which play a protective role in breast cancer (Birrell et al., 2007). This 
indicates that the androgenic actions of MPA in breast cancer is not straightforward. Like MPA, 
progestins such as NET-A, LNG and GES, have also been shown to be potent AR agonists 
(Africander et al. 2014; Louw-du Toit et al. 2017a). Whether the progestins displaying androgenic 
properties similar to DHT would increase ERβ expression, is not known. Furthermore, whether 
androgens and/or androgenic progestins would regulate ERα expression is also not known, and 
warrants further investigation. 
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1.5 Conclusion 
Considering that breast cancer is the most commonly diagnosed cancer among women worldwide 
(Ferlay et al., 2015; Torre et al., 2015; Siegel et al., 2016), it is important to understand the underlying 
mechanisms so as to facilitate the design of new drugs for the treatment and prevention of breast 
cancer. All members of the steroid receptor family have been implicated in breast cancer 
pathogenesis, and often these steroid receptors influence each other’s activity (reviewed in (Sikora 
2016; Perkins et al. 2018)). For example, the AR is expressed in the majority of ERα-positive breast 
cancers (Agoff et al., 2003; Niemeier et al., 2010; Tsang et al., 2014), and has been associated with 
a growth-inhibitory role (Castellano et al., 2010; Hu et al., 2011; Park et al., 2011; Tsang et al., 2014). 
Several mechanisms have been proposed for this inhibition, which all involve crosstalk of the AR 
with the ER subtypes (Figure 1.3) (Peters et al., 2009; Rizza et al., 2014). One mechanism involves 
the DHT-activated AR inhibiting the transcriptional activity of ERα (Peters et al., 2009). 
Interestingly, activation of the AR by MPA, also resulted in this inhibition of ERα activity (Peters et 
al., 2009). Another mechanism involves the Mib- and DHT-activated AR increasing ERβ mRNA and 
protein expression (Rizza et al., 2014). Considering that MPA, NET-A and LNG display similar 
androgenic properties as DHT (Africander et al. 2014; Louw-du Toit et al. 2017a), and that they have 
previously been associated with increased breast cancer risk (Rossouw et al., 2002; Beral et al., 2003; 
Fournier et al., 2008), the question arises whether these progestins would also increase ERβ 
expression via an AR-mediated mechanism. Moreover, as ERβ and ERα play opposing roles in breast 
cancer, it is important to also assess AR-mediated effects of the androgens and progestins on ERα 
expression. In view of the wide-spread expression of the AR in ER-positive breast cancer (Søreide et 
al., 1992; Garay and Park, 2012), it is not surprising that AR-targeted breast cancer treatment is 
actively being researched (reviewed in (Rahim & O’Regan 2017)). In fact, MPA has been used in 
breast cancer treatment, and the AR has been shown to be required for its effects (Birrell et al. 1995a). 
Considering the above, and the fact that the role of progestins in breast cancer is not straightforward, 
it is crucial to investigate the AR-mediated effects of progestins binding to the AR.  
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Figure 1.3. Interplay between the AR and ER subtypes may lead to positive effects on breast cancer. 
ERα promotes cell survival and proliferation, while ERβ antagonizes ERα-mediated effects. In ER-positive 
breast cancer, the androgen-activated AR inhibits cell proliferation by inhibiting the activity of ERα and 
upregulating ERβ expression. Effects of the progestin-activated AR on the expression of both ERβ and ERα 
are unknown.  
 
 
1.6 Hypothesis and aims of study 
Rizza and co-workers have shown that activation of the AR by the natural androgen, DHT, and a 
potent synthetic non-metabolizable androgen, Mib, leads to the upregulation of ERβ expression  
(Rizza et al., 2014). Whether these androgens elicit similar effects on ERα expression was not 
investigated. However, considering that ERα is associated with a proliferative role in breast cancer, 
and that anti-proliferative effects were observed when ERβ expression was increased, one would not 
expect to see increased ERα expression in the presence of these androgens. Some progestins used in 
contraception and menopausal HT can bind to the AR and display androgenic properties similar to 
DHT, while others display anti-androgenic properties similar to natural P4. The primary hypothesis 
of this study was thus that the androgenic progestins, unlike P4 and the anti-androgenic progestins, 
would increase the expression of ERβ, but not ERα, via a mechanism requiring the AR. In order to 
test the hypothesis, the aims of this study were as follows: 
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1. To compare the potential of the progestins displaying androgenic and anti-androgenic activity 
to either induce the AR N/C interaction, or antagonize the DHT-induced AR N/C interaction, 
as a measure of conformational change and activation of the AR. Mammalian two-hybrid 
assays were performed in the COS-1 African monkey kidney fibroblast cell line.  
 
2. To investigate whether progestins known to bind to the AR and display androgenic properties, 
would protect the AR protein from degradation. Western blot analysis was performed in the 
MCF-7 BUS breast cancer cell line.  
 
3. To investigate the steroid receptor-mediated effects of androgens, P4, as well as the 
androgenic- and anti-androgenic progestins on proliferation of the MCF-7 BUS and T47D 
breast cancer cells, using cell viability assays and steroid receptor-specific antagonists.  
 
4. To directly compare the effects of androgens, P4, as well as the androgenic- and anti-
androgenic progestins on the mRNA and protein expression of ERβ and ERα in human breast 
cancer cell lines using real-time quantitative PCR and western blotting.  
 
5. To investigate the role of the AR in the response in (4), using an AR antagonist. 
 
Importantly, while the terms “we” and “our” are often used throughout this thesis, all experimental 
work was performed by the candidate.  
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Chapter 2 
Materials and Methods
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2.1 Test compounds 
The compounds used in this study (Table 2.1) were mostly purchased from Sigma-Aldrich, South 
Africa, except mibolerone (Mib), which was purchased from Steraloids, United States of America 
(USA). Stock solutions of the test compounds were prepared in absolute ethanol (EtOH), and stored 
at −20˚C. For all assays, the test compounds were diluted 1000 times in serum-free culturing medium, 
so that the final concentration of EtOH was 0.1% (v/v). Thus, 0.1% (v/v) EtOH served as a vehicle 
control in all experiments. 
 
Table 2.1. Agonists and antagonists used in this study. 
  
  Common name Chemical name Abbreviation 
A
go
ni
st
s 
Androgens 
Natural Dihydrotestosterone 5α-androstan-17β-ol-3-one DHT 
Synthetic Mibolerone  17β-hydroxy-7α, 17α-dimethylestr-4-en-
3-one 
Mib 
Progestogens 
Natural Progesterone  4-pregnene-3, 20-dione P4 
Synthetic 
Medroxy-
progesterone acetate  
6α-methyl-17α-hydroxy-progesterone 
acetate 
MPA 
Norethisterone 
acetate  
17α-ethynyl-19-nortesterone 17β-acetate NET-A 
Levonorgestrel  
17α-ethynyl-17β-hydroxy-18α-homoestr-
4-en-3-one 
LNG 
Gestodene  
17α-13-ethyl-17-hydroxy-18,19-
dinorpregna-5,15-dien-20-yn-3-one 
GES 
Nesterone  
17α-acetoxy-16-methylene-19-
norprogesterone 
NES 
Nomegestrol acetate  
17α-acetoxy-6-methyl-6-dehydro-19-
norprogesterone 
NOMAC 
Drospirenone  6β,7β:15β,16β-dimethylenespirolactone DRSP 
Promegestone 
(17β)-17-methyl-17-propanoylestra-4,9-
dien-3-one 
R5020 
Estrogens Natural 17β-Estradiol  17β-estra-1, 3, 5 (10)-triene-3, 17-diol  E2 
Gluco-
corticoids Synthetic Dexamethasone 
(11β,16α)-9-Fluoro-11,17,21-trihydroxy-
16-methylpregna-1,4-diene-3,20-dione 
Dex 
A
nt
ag
on
is
ts
 
AR 
Hydroxyflutamide  
2-hydroxy-2-methyl-N-[4-nitro-3-
(trifluoromethyl)-phenyl]propanamide 
OHF 
Bicalutamide 
N-(4-cyano-3-(trifluoromethyl)phenyl)-
3-((4-fluorophenyl)sulfonyl)-2-hydroxy-
2-methylpropanamide 
Bical 
ER 
Fulvestrant  
ICI 182,780  
7α-(9-(4,4,5,5,5-
pentafluoropentylsulfinyl)-nonyl)estra-
1,3,5(10)-triene-3,17β-diol 
ICI 
PR/GR/ 
AR 
Mifepristone  
11β-[4-(dimethylamino)-phenyl]-17β-
hydroxy-17α-(prop-1-yn-1-yl)estra-4,9-
dien-3-one 
RU486 
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2.2 Cell culture 
The T47D human breast cancer cell line was a kind gift from Prof. I. Parker (University of Cape 
Town, South Africa), while the COS-1 African monkey kidney fibroblast cells and HEK-293 human 
embryonic kidney cells, were obtained from the American Type Culture Collection (ATCC) (USA). 
All these cell lines were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 
phenol-red and 4.5 g/mL glucose (Sigma-Aldrich, South Africa), supplemented with 10% (v/v) fetal 
calf serum (FCS) (Separations, South Africa), 100 IU/mL penicillin and 100 µg/mL streptomycin 
(PenStrep) (Sigma-Aldrich, South Africa). The MDA-MB-453 triple negative human breast cancer 
cell line, a kind gift from Prof. A. Edkins (Rhodes University, South Africa), was maintained in the 
same medium as above, with the addition of 2 mM L-glutamine (Sigma-Aldrich, South Africa). The 
MCF-7 BUS human breast cancer cell line, obtained from Prof. A. Soto (Tufts University, 
Massachusetts), was maintained in DMEM containing phenol-red and 4.5 g/mL glucose, 
supplemented with 5% (v/v) heat-inactivated FCS (Addendum A) and PenStrep. All experiments 
were conducted within the first 35 passages since the cells were thawed from storage. Cells were 
tested regularly for mycoplasma contamination by means of Hoechst staining (Freshney et al., 1987), 
and only mycoplasma negative cell lines were used in experiments. Representative mycoplasma 
negative images of the cell lines used in this study are shown in Figure B1 (Addendum B). All cell 
lines were maintained in 75 cm2 culture flasks (Bio-Smart Scientific, South Africa) and incubated at 
37˚C in 90% humidity and 5% CO2.  
 
2.3 Plasmids 
The cDNA expression vectors for the human wild-type AR DBD-LBD (pSG5-hAR (DBD-LBD)), 
and the human AR NTD-VP16 fusion protein (pSNATCH-II-hAR (NTD)), were obtained from Prof. 
F. Claessens (University of Leuven, Belgium) (Alen et al., 1999). The luciferase promoter-reporter 
construct, pTAT-GRE-E1b-luc, which is driven by the E1b promoter and contains two copies of the 
rat tyrosine aminotransferase (TAT)-GRE, was provided by Prof. G. Jenster (Erasmus University of 
Rotterdam, Netherlands) (Jenster et al., 1997). Plasmids expressing the human PR-A and PR-B 
isoforms (pSG5-hPR-A and pSG5-hPR-B), were obtained from Prof. E. Kalkhoven (University of 
Utrecht, Netherlands) (Kalkhoven et al., 1996), while the human wild-type AR (pSG5-hAR) was a 
kind gift from Dr. H. Klocker (Medical University of Innsbruck, Austria) (Schneikert et al., 1996). 
The plasmid expressing the human GR (pRS-hGRα) was obtained from Prof. R. Evans (Harvard 
Hughes Medical Institute, USA) (Arriza et al., 1987), while the plasmids expressing human ERα 
(pSG5-hERα) and ERβ (pSG5-hERβ) were received from Prof. F. Gannon (European Molecular 
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Biology Laboratory, Germany) (Flouriot et al., 2000). The empty pSG5-expression vector was a gift 
from Prof. G. Mellgren (University of Bergen, Norway). 
 
2.4 Plasmid DNA preparation 
Competent Escherichia coli (E. coli) DH5α cells were transformed with the respective expression 
vectors using the heat shock method as previously described by Cohen et al. (1972). Transformed E. 
coli cells were grown on Luria-Bertani (LB) agar (Sigma-Aldrich, South Africa) plates (Addendum 
A) containing 0.1% (w/v) ampicillin (Sigma-Aldrich, South Africa), as all the plasmids used in this 
study contained an ampicillin resistance gene. A starter culture was prepared by inoculating a single 
transformed colony in 25 mL LB medium (Sigma-Aldrich, South Africa) (Addendum A) containing 
0.1% (w/v) ampicillin and growing the culture at 37˚C for 6 hours at 150 revolutions per minute 
(rpm). An overnight culture was then prepared by transferring 250 µL of the starter culture to 250 
mL LB medium containing 0.1% (w/v) ampicillin, and was grown at 37˚C for 16 hours at 150 rpm. 
In order to collect the bacterial cells, the cultures were centrifuged at 6000 x g for 10 minutes at 4˚C. 
Following centrifugation, the supernatant was discarded and the plasmid DNA was isolated using the 
Macherey-Nagel Nucleobond® Xtra Maxi kit (Separations Scientific, South Africa) according to the 
manufacturer’s instructions. Cell pellets were resuspended in 12 mL resuspension buffer containing 
RNase A, and the cells were subsequently lysed by adding 12 mL lysis buffer and inverting the 
solution 5 times. The cell suspension was then incubated for 5 minutes at room temperature. 
Following incubation, 12 mL neutralization buffer was added and the solution inverted 15 times. The 
plasmid DNA was then purified using the Nucleobond® Xtra Maxi column with a filter insert, which 
was first equilibrated by adding 25 mL equilibration buffer. The cell lysate was then applied to the 
column filter. Once the cell debris was removed by gravitational flow, 15 mL of the equilibration 
buffer was allowed to flow through the column filter by gravitational flow. The filter was then 
discarded and the column washed with 25 mL wash buffer. The plasmid DNA was eluted by adding 
15 mL elution buffer to the column. The eluate was collected in a 50 mL centrifuge tube to which 
10.5 mL isopropanol (Sigma-Aldrich, South Africa) was added. The plasmid DNA was precipitated 
by centrifugation at 15 000 x g for 30 minutes at 4˚C. The supernatant was discarded and the pellet 
washed with 5 mL 70% (v/v) EtOH, followed by centrifugation at 15 000 x g for 5 minutes at room 
temperature. The DNA pellet was allowed to dry at room temperature before resuspension in 1 mL 
nuclease-free water. The concentration and purity of the isolated plasmid DNA were determined 
using the NanoDrop 1000 (Inqaba Biotech, South Africa), while the size and integrity of the plasmid 
DNA was analyzed by restriction enzyme digest and agarose gel electrophoresis. 
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2.5 Total RNA isolation 
The human MCF-7 BUS, T47D and MDA-MB-453 breast cancer cell lines were maintained as 
described in Section 2.2. Cells were seeded into 12-well cell culture plates (Whitehead Scientific, 
South Africa) at a cell density of 1 x 105 cells per well in phenol red-free DMEM (Sigma-Aldrich, 
South Africa) supplemented with PenStrep (Sigma-Aldrich, South Africa), and either 5% (v/v) heat-
inactivated charcoal-stripped (CS)-FCS (Addendum A) (MCF-7 BUS), 10% (v/v) CS-FCS (T47D) 
or 10% (v/v) CS-FCS plus 2 mM L-glutamine (MDA-MB-453). Cells were allowed to settle for 24 
hours before treatment with unsupplemented phenol red-free DMEM containing either 0.1% (v/v) 
EtOH or 10 nM of the androgens and progestogens, in the absence and presence of 10 µM of the AR 
antagonist, OHF. Following incubation for 24 hours, the cells were washed with 1X phosphate-
buffered saline (PBS) (Sigma-Aldrich, South Africa) before lysis by adding 400 µL Tri-Reagent® 
(Sigma-Aldrich, South Africa) to each well. Lysates were then transferred to 1.5 mL microcentrifuge 
tubes and incubated for 5 minutes at room temperature. This was followed by the addition of 80 µL 
chloroform, vortexing of samples for 15 seconds, and incubation of samples at room temperature for 
3 minutes. Samples were subsequently centrifuged at 14 000 rpm for 20 minutes at 4°C for separation 
into three distinct phases: a clear aqueous phase containing RNA, an interphase containing DNA, and 
a pink organic phase containing protein. The RNA-containing aqueous phase was transferred to a 
clean 1.5 mL microcentrifuge tube and an equal volume of ice-cold isopropanol was added. Samples 
were vortexed for 5 seconds, incubated for 15 minutes at room temperature and centrifuged at 14 000 
rpm for 15 minutes at 4°C. The supernatant was discarded and the RNA pellets were washed with 
500 µL 75% (v/v) EtOH in diethyl pyrocarbonate (DEPC)-treated water. Samples were vortexed for 
1 minute and centrifuged at 8 000 rpm for 10 minutes at 4°C. Thereafter, the supernatant was 
discarded and the RNA pellets were allowed to air dry on ice. The RNA pellets were subsequently 
dissolved in 15 µL DEPC-treated water. The concentration and purity of each sample was measured 
using the NanoDrop 1000 (Inqaba Biotech, South Africa), while the integrity of the RNA was 
confirmed by assessing the presence of intact 18S and 28S ribosomal RNA subunits using denaturing 
agarose gel electrophoresis (Figure C1, Addendum C). All RNA samples were subsequently stored 
at -80°C. 
 
2.6 cDNA synthesis 
Following the total RNA isolation, cDNA was synthesized by reverse transcription of the RNA using 
the Promega ImProm-II™ reverse transcription system (Anatech, South Africa) as per the 
manufacturer’s instructions. Briefly, 0.5 µg total RNA, a final concentration of 30 ng/µL oligo(dT)15 
primer and PCR-grade water (where needed) was added to a final volume of 2.5 µL in a thin-walled 
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PCR tube. To denature the RNA secondary structures, the template-primer mixture was incubated for 
5 minutes at 70°C and subsequently placed on ice for 5 minutes. A master mix containing the rest of 
the components needed for the reverse transcription process was prepared by adding 3.5 µL PCR-
grade water, 2 µL Im-Prom-II™ 5X reaction buffer, 0.75 µL MgCl2 (final concentration of 1.5 mM), 
0.5 µL deoxynucleotide triphosphate (dNTP) mix (final concentration of 0.5 nM for each nucleotide), 
0.25 µL recombinant RNasin ribonuclease inhibitor (10 U per reaction), and 0.5 µL ImProm-II 
reverse transcriptase (80 U per reaction), per RNA sample. A volume of 7.5 µL of the master mix 
was added to each tube containing the denatured RNA and samples were incubated for 5 minutes at 
25°C to allow for annealing of the primers, followed by incubation for 1 hour at 45°C for extension. 
Thereafter, samples were incubated for an additional 15 minutes at 70°C to inactivate the Im-Prom-
II™ reverse transcriptase enzyme. All cDNA samples were stored at -20°C until analysis. 
 
2.7 Real-time quantitative polymerase chain reaction (qPCR) 
The relative mRNA expression levels of ERα, ERβ and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) were determined by real-time qPCR using the primers described in Table 2.2, the KAPA 
SYBR FAST® qPCR master mix (Roche Applied Science, South Africa), and the LightCycler 96 
system (Roche Applied Science, South Africa) according to the manufacturer’s instructions. The 
reaction mixture per well of the PCR plate was as follows: 1 µL cDNA or PCR-grade water (negative 
control), forward and reverse primers (final concentration of 0.5 µM each), 5 µL KAPA SYBR 
FAST® qPCR master mix, and PCR-grade water to a final volume of 10 µL. PCR plates containing 
the samples were pre-incubated in the LightCycler 96 system for 5 minutes at 95°C in order to activate 
the Taq polymerase. Details of the three subsequent PCR amplification steps are described in Table 
2.2. Quantification cycle (Cq) values were used to calculate the relative transcript levels of ERα, ERβ 
and GAPDH using the mathematical method previously described by Pfaffl (2001). GAPDH was 
used as an internal control. Further details on the real-time qPCR method, such as primer efficiencies 
and melting curve analysis, are discussed in Addendum C. 
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Table 2.2. Primer sequences and thermal cycling conditions for genes investigated in this study.  
Gene Primers (5’ – 3’) Strand 
Amplicon 
length 
(bp) 
Thermal cycling profile 
Reference 
Denaturation Annealing Elongation 
Number 
of cycles 
ERα 
AGATCTTCGACATGCTGCTGGCTA Forward 
137 
95˚C for 
3 s 
63˚C for 
20 s 
72˚C for 
10 s 
43 
Qiao et al. 
(2012) AGACTTCAGGGTGCTGGACAGAAA Reverse 
ERβ 
TAGTGGTCCATCGCCAGTTAT Forward 
393 
95˚C for 
30 s 
56˚C for 
15 s 
72˚C for 
60 s 
40 
Enmark et 
al. (1997) 
GGGAGCCACACTTCACCAT Reverse 
GAPDH 
TGAACGGGAAGCTCACTGG Forward 
307 
95˚C for 
10 s 
59˚C for 
10 s 
72˚C for 
12 s 
35 
Ishibashi 
et al. 
(2003) TCCACCACCCTGTTGCTGTA Reverse 
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2.8 Western blot 
For the characterization of the MCF-7 BUS, T47D and MDA-MB-453 human breast cancer cell lines 
in terms of their steroid receptor content, cells were maintained as described in Section 2.2, and 
seeded into 12-well cell culture plates at a density of 1 x 105 cells per well. For positive controls, 
COS-1 cells were transiently transfected with 250 ng of the expression vectors for the GR, PR-A or 
PR-B isoforms, while HEK-293 cells were transiently transfected with expression vectors for the AR, 
ERα or ERβ, using XtremeGENE HP DNA transfection reagent (Roche Applied Science, South 
Africa) as per the manufacturer’s instructions. Untransfected COS-1 and HEK-293 cells were used 
as negative controls. All cells were grown until 100% confluency and washed with 1X PBS before 
cell lysis in 80 µL 2X Laemmli buffer (Addendum A). Cell lysates were denatured by boiling for 10 
minutes at 97°C, and samples stored at -20°C until analysis.  
For investigation into the effects of the test compounds on AR, ERα and ERβ protein expression, 
MCF-7 BUS or MDA-MB-453 cells were seeded into 12-well cell culture plates at a density of 1 x 
105 cells per well and treated for 24 hours with unsupplemented phenol red-free DMEM containing 
either 0.1% (v/v) EtOH or 10 nM of the test compounds in the absence and presence of 10 µM of the 
AR antagonist, OHF. Following treatment, cell lysates were prepared and denatured as described 
above.  
Proteins were separated on a 10% SDS-polyacrylamide gel in 1X SDS-PAGE Running Buffer 
(Addendum A) at 100 V for 15 minutes and then at 200 V for 30 - 45 minutes. The PageRuler™ 
Prestained Protein Ladder (Thermo Fisher Scientific, South Africa) was loaded onto each SDS-
polyacrylamide gel in order to determine protein sizes. Following electrophoresis, proteins were 
electroblotted onto nitrocellulose membranes (AEC-Amersham Biosciences, South Africa) at 180 
mA for 2 hours in ice-cold 1X Transfer Buffer (Addendum A) using a mini Trans-Blot system (Bio-
Rad, South Africa). Membranes were subsequently blocked for 90 minutes in 10% (w/v) fat-free milk 
powder prepared in Tris-buffered saline (TBS) containing 0.1% (v/v) Tween-20 (Sigma Aldrich, 
South Africa) (TBST) (Addendum A). Thereafter, the membranes were rinsed with TBST and 
subsequently probed for 16 hours at 4°C with the appropriate primary antibody at the dilutions 
specified in Table 2.3. GAPDH was used as the loading control. Membranes were then washed once 
for 15 minutes and thrice for 5 minutes using TBST. Following the wash steps, the membranes were 
incubated with either goat anti-rabbit or mouse IgG kappa binding protein (IgGκ BP) horseradish 
peroxidase (HRP)-conjugated secondary antibodies (Table 2.3) for 90 minutes at room temperature. 
The membranes were subsequently washed as above, and proteins visualized using the Clarity™ 
Western ECL Substrate (Bio-Rad, South Africa) and the MyECL imaging system (Thermo Fisher 
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Scientific, South Africa) according to the manufacturer’s instructions. The MyImageAnalysis™ 
software (Thermo Fisher Scientific, South Africa) was used to analyze and quantify protein 
expression. 
 
Table 2.3. Primary and secondary antibody dilutions used for western blotting. 
Protein Primary antibody Dilution 
HRP-conjugated 
secondary antibody 
Dilution 
AR AR (441) 1:1000 Mouse IgGκ BP 1:3000 
ERα ERα (F-10) 1:1000 Mouse IgGκ BP  1:1000 
ERβ 
ERβ (EPR3777) 1:500 
Goat anti-rabbit 1:1000 
ERβ (EPR20743) 1:1000 
GR GR (H-300) 1:2000 Goat anti-rabbit 1:3000 
PR-A/B PR (NCL-L-PGR-312) 1:1000 Mouse IgGκ BP 1:2000 
GAPDH GAPDH (0411) 1:3000 Mouse IgGκ BP 1:3000 
All antibodies, except the ERβ and PR-A/B antibodies, were obtained from Santa Cruz Biotechnology, Inc., 
Europe. The ERβ antibodies were purchased from Abcam, USA, while the PR-A/B primary antibody was 
purchased from Leica Biosystems Inc., USA.  
 
2.9 Mammalian two-hybrid assay 
Mammalian two-hybrid assays, illustrated in Figure 2.1, were performed as previously described by 
Africander et al. (2014) with minor modifications. Briefly, COS-1 cells were seeded into 10 cm cell 
culture dishes at a density of 2 x 106 cells in phenol red-free DMEM supplemented with 10% (v/v) 
CS-FCS and PenStrep. The next day, cells were transiently transfected with 6.67 µg of the pTAT-
GRE-E1b-luc promoter-reporter construct (referred to as the classical ARE), 0.67 µg of pSG5-hAR 
(DBD-LBD) and 0.67 µg of pSNATCH-II-hAR (NTD), using XtremeGENE HP DNA transfection 
reagent (Roche Applied Science, South Africa) according to the manufacturer’s instructions. 
Following a 24-hour incubation period, cells were trypsinized and re-seeded into 96-well cell culture 
plates at a density of 1 x 104 cells per well and allowed to settle. Cells were then treated for 24 hours 
with unsupplemented phenol red-free DMEM containing either 0.2% (v/v) EtOH or (i) 100 nM DHT 
or the progestogens (agonist mode) or (ii) 100 nM DHT in the absence and presence of increasing 
concentrations of the progestogens (antagonist mode). Following treatment, cells were washed with 
1X PBS and lysed using 25 µL passive lysis buffer (Addendum A). The luciferase activity in the cell 
lysates was measured using the Luciferase Assay System (Promega, USA) and a Veritas microplate 
luminometer (Whitehead Scientific, South Africa). The values obtained were expressed in relative 
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light units (RLU) and normalized to the total protein concentration (mg/mL), which was determined 
using the Bradford protein determination method (Bradford 1976).  
 
 
 
Figure 2.1. Principle of the mammalian two-hybrid assay used to study the AR N/C interaction. The 
interaction between the N-terminal domain (NTD) and carboxyl-terminal of the AR (so-called AR N/C 
interaction) was studied using the in vitro mammalian two-hybrid assay. Vectors encoding the carboxyl-
terminal AR ligand binding domain (LBD) fused to the DNA binding domain (DBD) of the AR (pSG5-hAR 
(DBD-LBD)), as well as the NTD of the AR fused to the activation domain of the herpes simplex virus protein, 
VP16 (pSNATCH-II-hAR (NTD)), were co-transfected into the COS-1 cell line together with a classical 
androgen response element (ARE)-driven luciferase reporter construct. Cells were treated with the test 
compounds, and their ability to induce the AR N/C interaction or antagonize the DHT-induced AR N/C 
interaction was determined by measuring luciferase activity using a luminometer. Figure adapted from 
Africander et al. (2014).  
 
2.10 Cell viability assay 
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell viability assay was 
used to measure breast cancer cell proliferation. The human T47D and MCF-7 BUS breast cancer 
cell lines were maintained as described in Section 2.2 and seeded into 96-well cell culture plates at   
5 x 103 cells per well in phenol red-free DMEM supplemented with PenStrep, and either 10% (v/v) 
CS-FCS (T47D) or 5% (v/v) heat-inactivated CS-FCS (MCF-7 BUS). The MDA-MB-453 breast 
cancer cell line was maintained as described in Section 2.2, and plated in 6 cm cell culture dishes at 
a density of 8 x 105 cells in phenol-red DMEM supplemented with PenStrep, 10% (v/v) FCS and 2 
mM L-glutamine. The next day, MDA-MB-453 cells were transiently transfected with 300 ng of the 
expression vectors for (i) ERα or (ii) ERα and ERβ using XtremeGENE HP DNA transfection reagent 
(Roche Applied Science, South Africa) according to the manufacturer’s instructions. Following a 24-
hour incubation period, the MDA-MB-453 cells were trypsinized and re-seeded into 96-well cell 
culture plates at a density of 5 x 103 cells per well in phenol red-free DMEM supplemented with 
PenStrep, 10% (v/v) FCS and 2 mM L-glutamine. The next day, the MDA-MB-453 cells were treated 
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with either 0.1% (v/v) EtOH or increasing concentrations of E2, in the absence and presence of 
equimolar concentrations of DHT. Twenty-four hours after the T47D and MCF-7 BUS cells were 
seeded, these cells were treated with either 0.2% (v/v) EtOH or 10 nM Mib, DHT, or the 
progestogens, in the absence and presence of either 1 or 10 µM steroid receptor-selective antagonist. 
Following a 72-hour incubation period, all cells were re-treated with the test compounds for an 
additional 44 hours, before incubation with pre-warmed 5 mg/mL MTT (Addendum A) solution for 
4 hours. The medium was carefully aspirated and 200 µL of dimethyl sulfoxide (DMSO) (Sigma-
Aldrich, South Africa) was added to each well in order to solubilize the formazan crystals. 
Absorbances were then measured at 550 nm using the BioTek® Power Wave 340 microplate 
spectrophotometer (Analytical and Diagnostic Products, South Africa). Results were represented as 
fold induction relative to the vehicle control (0.1 or 0.2% EtOH), which was set as one. 
 
2.11 Data manipulation and statistical analysis 
GraphPad Prism® version 7.00 (GraphPad Software, USA) was used for statistical analysis and 
graphical representation. Statistical significance of ungrouped data was determined using one-way 
analysis of variance (ANOVA) with either Dunnett’s (compares all columns vs. control column), 
Bonferroni’s (compares all columns to each other) or Newman Keuls (compares all columns to each 
other) as post-test. Statistical analyses on data with two or more data sets (grouped data) were 
performed using two-way ANOVA with Bonferroni’s (compares all pairs of columns) as post-test, 
unless otherwise indicated. Statistical significance is denoted by either *, **, or ***, to indicate 
p<0.05, p<0.01 or p<0.001, respectively, while no statistical significance (p>0.05) is denoted by ns. 
Alphabetical letters are also used to indicate statistical significance, where values that are statistically 
different are assigned different letters. Unless otherwise indicated, the error bars represent the 
standard error of the mean (SEM) of three independent experiments.
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3.1 Progestins elicit different AR conformations. 
A number of parameters contribute to the biological activity of a ligand via a steroid receptor, and 
include the affinity of the ligand for the receptor, the rate of its nuclear translocation, the induced 
receptor conformation and recruitment of co-regulators (Griekspoor et al., 2007). In terms of the AR, 
the interaction between the amino- and carboxyl-terminal of the AR, commonly known as the AR 
N/C interaction has been well described for AR agonists (He et al., 1999, 2000; Kemppainen et al., 
1999; Schaufele et al., 2005; Van Royen et al., 2007, 2012; Africander et al., 2014). Interestingly, it 
has previously been shown that while both the first generation progestins, MPA and NET-A, display 
androgenic properties similar to each other and the natural androgen DHT, only DHT and NET-A 
could induce the AR N/C interaction (Africander et al., 2014). MPA on the other hand, has been 
shown to be an antagonist of the DHT-induced AR N/C interaction (Kemppainen et al., 1999; Tanner, 
2002). It has recently been shown that LNG and GES also display androgenic activity similar to DHT, 
while NES, NOMAC and DRSP display anti-androgenic activity similar to the natural progestogen, 
P4 (Louw-du Toit et al. 2017a). Whether these progestins induce or antagonize the AR N/C 
interaction is not known. A mammalian two-hybrid assay was thus used to compare the potential of 
LNG, GES, NES, NOMAC and DRSP to induce the AR N/C interaction. COS-1 cells were transiently 
transfected with a promoter reporter construct, the expression vector encoding the human AR DBD-
LBD and the expression vector encoding the human AR NTD. Results in Figure 3.1A show that LNG 
and GES induce the AR N/C interaction to the same extent as each other and NET-A, but weaker 
than DHT. In contrast, NES, NOMAC, and DRSP did not induce the AR N/C interaction (Figure 
3.1A). The result showing that P4 and MPA do not induce the AR N/C interaction, while NET-A does, 
is consistent with the previous study from our group (Africander et al., 2014). None of the progestins, 
except MPA, inhibited the DHT-induced AR N/C interaction (Figure 3.1B).  
 
3.2 Unlike the androgens Mib and DHT, the progestogens do not influence AR 
protein levels in the MCF-7 BUS breast cancer cell line. 
It is known that the binding of androgens to the AR stabilizes the AR protein, while the binding of 
anti-androgens result in AR protein degradation (Kemppainen et al., 1992; Zhou et al., 1995). We 
thus evaluated whether progestins with androgenic activity similar to DHT would stabilize AR 
protein in a similar manner as DHT, while progestins with anti-androgenic activity similar to P4, 
would cause AR degradation. Western blot analysis was performed with lysates from the MCF-7 
BUS breast cancer cell line treated with the androgens, Mib and DHT, the androgenic progestins, 
MPA, NET-A and LNG, or the anti-androgenic progestogens, P4, NES and NOMAC, in the absence 
and presence of the AR antagonist, OHF. The results showed that both Mib and DHT increase AR 
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protein levels (Figure 3.2B), indicating stabilization of the AR protein. The Mib- and DHT-induced 
increase was inhibited in the presence of the AR antagonist, OHF (Figure 3.2C). Knowing that 
androgens stabilize the AR protein, while it is degraded by anti-androgens, it was surprising that 
neither the androgenic nor anti-androgenic progestogens affected AR protein levels in the MCF-7 
BUS cell line (Figure 3.2B). 
 
   
 
Figure 3.1. (A) LNG and GES, induce the AR N/C interaction, while NES, NOMAC and DRSP do not. 
(B) Only MPA antagonizes the DHT-induced AR N/C interaction and in a dose-dependent manner. 
COS-1 cells were transiently transfected with the pTAT-GRE-E1b-luc promoter-reporter construct, as well as 
the pSNATCH-II-hAR (NTD) and wild-type pSG5-hAR (DBD-LBD) expression vectors. Cells were 
incubated for 24 hours with either 0.2% (v/v) EtOH (vehicle), (A) 100 nM DHT, P4, MPA, NET-A, LNG, 
GES, NES, NOMAC or DRSP, or (B) 100 nM DHT, in the absence and presence of increasing concentrations 
of P4, MPA, NET-A, LNG, GES, NES, NOMAC or DRSP. Luciferase activity was measured in relative light 
units and normalized to the protein concentration determined using the Bradford method (Bradford, 1976). 
Induction is shown as % luciferase activity relative to DHT = 100%. The result shown is the average of at least 
three independent experiments with each condition performed in triplicate (± SEM). Statistical analysis was 
performed using one-way ANOVA with Bonferroni’s (compares all columns to each other) as post-test. 
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Figure 3.2. Progestogens, unlike Mib and DHT, do not influence AR protein levels in MCF-7 BUS cells. 
The human MCF-7 BUS breast cancer cells were treated for 24 hours with either 0.2% (v/v) EtOH (vehicle) 
or 10 nM Mib, DHT, P4, MPA, NET-A, LNG, NES or NOMAC, in the absence and presence of 10 µM OHF. 
Protein lysates were analyzed by western blotting using primary antibodies specific for the AR and GAPDH 
(loading control). HEK-293 cells transiently transfected with an expression vector for the AR was used as a 
positive control, while untransfected COS-1 cells were used as a negative control. (A) A representative western 
blot of at least three independent experiments is shown. (B, C) AR and GAPDH protein expression was 
quantified using the MyImageAnalysis™ software, and AR expression was normalized to GAPDH expression. 
The results shown are the averages (± SEM) of at least three independent experiments. Statistical analysis was 
performed using (B) one-way ANOVA with Dunnett’s (compares all columns vs. control column) as post-test 
or (C) two-way ANOVA with Bonferroni’s (compares all pairs of columns) as post-test. 
Ve
hic
le
MI
B
DH
T P 4
MP
A
NE
T-A LN
G
NE
S
NO
MA
C
0
2
4
6
8
10 nM Test Compound
A
R
/G
A
PD
H
 
pr
ot
ei
n 
ex
pr
es
si
on
 
± 
SE
M
 (E
tO
H
 =
 1
)
ns
*** ***
Ve
hic
le
MI
B
DH
T P 4
MP
A
NE
T-A LN
G
NE
S
NO
MA
C
0
2
4
6
8
A
R
/G
A
PD
H
 
pr
ot
ei
n 
ex
pr
es
si
on
 
± 
SE
M
 (E
tO
H
 =
 1
)
10 nM Compound
+ 10 µM OHF
*** ***
ns
ns ns
ns
ns
ns
ns
B 
C 
A 
Stellenbosch University  https://scholar.sun.ac.za
  40 
3.3 All progestogens increase proliferation of the human MCF-7 BUS and T47D 
breast cancer cell lines to the same extent.  
Results from in vitro studies investigating the effects of androgens and progestogens on breast cancer 
cell proliferation are conflicting, with some studies showing increased proliferation (Birrell et al. 
1995b; Schoonen et al. 1995a; Schoonen et al. 1995b), while others show a decrease (Botella et al., 
1994; Formby and Wiley, 1998; Peters et al., 2009), or no effect (Van Der Burg et al., 1992; Catherino 
et al., 1993; Ruan et al., 2012). We thus directly compared the effects of the selected progestins 
relative to each other, P4, the synthetic androgen, Mib, and natural androgen, DHT, on the 
proliferation of the MCF-7 BUS and T47D breast cancer cell lines. Both these cell lines are widely 
used in breast cancer research (Aka and Lin, 2012). The results show that all progestins increase 
breast cancer cell proliferation to the same extent as each other and DHT in T47D cells (Figure 3.3B). 
Similar results were observed in the MCF-7 BUS cells, except that LNG does not the increase cell 
proliferation to the same extent as DHT (Figure 3.3A). 
 
 
 
           
Figure 3.3. All progestogens increase human breast cancer cell proliferation. The human (A) MCF-7 BUS 
and (B) T47D breast cancer cell lines were treated with either 0.1% (v/v) EtOH (vehicle) or 10 nM Mib, DHT, 
P4, MPA, NET-A, LNG or NES for 72 hours. The medium was aspirated and cells were re-treated for an 
additional 44 hours. Cell proliferation was measured using the MTT cell viability assay. Results are 
represented as fold proliferation relative to the vehicle control set as one. Results shown are the averages (± 
SEM) of at least three independent experiments with each condition performed in triplicate. Statistical analysis 
was performed using one-way ANOVA with Newman-Keuls (compares all columns to each other) as post-
test. 
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3.4 While the AR mediates the proliferative effects of MPA, NET-A and LNG in the 
MCF-7 BUS breast cancer cells, multiple receptors are required for their proliferative 
effects in the T47D breast cancer cells. 
Having shown that progestins known to display androgenic properties, with the exception of LNG in 
the MCF-7 BUS cells, increase breast cancer cell proliferation to the same extent as DHT, we 
postulated that the AR may be mediating these effects. However, as some progestins bind to multiple 
steroid receptors, we also investigated the role of the PR, GR and ER. First, we confirmed previous 
reports that the MCF-7 BUS and T47D human breast cancer cell lines express all of the above-
mentioned steroid receptors (Horwitz et al., 1975, 1978; Vladusic et al., 2000; Singer et al., 2003). 
Western blot analysis of the cell lysates showed that both the MCF-7 BUS and the T47D cell lines 
express PR-A, PR-B, the AR, GR, ERα and ERβ (Figure 3.4).  
 
 
Figure 3.4. MCF-7 BUS and T47D breast cancer cell lines both express endogenous PR-A, PR-B, AR, 
GR, ERα and ERβ. Whole cell extracts were prepared from MCF-7 BUS and T47D cells and analyzed by 
western blotting using primary antibodies specific for PR-A/B, AR, GR, ERα, ERβ and GAPDH (loading 
control). COS-1 cells transiently transfected with expression vectors for either PR-A, PR-B or GR, or HEK-
293 cells transiently transfected with expression vectors for either the AR, ERα or ERβ, were used as positive 
controls. Untransfected COS-1 or HEK-293 cells were used as negative controls. A representative western blot 
of at least three independent experiments is shown.  
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Next, the cells were treated with the androgens and progestogens in the absence and presence of 
specific steroid receptor antagonists. As expected, the results in Figure 3.5 show that the addition of 
the AR antagonist, OHF, inhibited the effects of Mib and DHT, confirming a previous report that 
these effects are mediated via the AR (Birrell et al. 1995b). OHF also significantly inhibited the 
effects of MPA, NET-A and LNG in the MCF-7 BUS cells (Figure 3.5A), suggesting that these effects 
are also mediated via the AR. We did not see any significant change in progestin-induced proliferation 
of the MCF-7 BUS cells in the presence of RU486, a well-known PR and GR antagonist (Spitz & 
Bardin 1993) (Figure 3.5C). Surprisingly, OHF only partially inhibited the effects of MPA, NET-A 
and LNG on T47D proliferation (Figure 3.5B), suggesting that the AR is not the only steroid receptor 
involved in mediating their effects in this cell line. The results in Figure 3.5D show that RU486 
decreases progestogen-induced proliferation of the T47D cells. Considering that we show that RU486 
acts as a PR-, but not a GR-, antagonist in this cell line (Figure B2, Addendum B), this result suggests 
that the PR is required for the effects of the progestogens on T47D cell proliferation. Interestingly, 
RU486 itself was shown to increase proliferation of both MCF-7 BUS (Figure 3.5C) and T47D 
(Figure 3.5D) breast cancer cells, which is consistent with previous studies showing that RU486 
elicits agonist activity in both these cell lines (Catherino et al., 1993; Kalkhoven et al., 1994). 
Although the results in Figure 3.5E show a decrease in MCF-7 BUS cell proliferation with all ligands 
in the presence of the ER antagonist, ICI, this was likely due to a decrease in cell viability induced 
by ICI (Figure B3, Addendum B). We could thus not draw any conclusions about the role of the ER 
in the proliferation of MCF-7 BUS cells. In contrast, ICI did not affect the viability of the T47D cells. 
The results in Figure 3.5F show that NET-A-induced proliferation of T47D cells was inhibited by 
ICI, while ICI partially inhibited LNG-induced proliferation. As neither NES nor P4 bind to the ER, 
nor display anti-androgenic properties, it was not surprising that they did not increase cell 
proliferation via the ER or AR in either cell line.
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Figure 3.5. While only the AR mediates the proliferative effects of MPA, NET-A and LNG in the MCF-
7 BUS cells, multiple receptors are required for their proliferative effects in the T47D cells. The human 
(A, C, E) MCF-7 BUS and (B, D, F) T47D breast cancer cells were treated with either 0.2% (v/v) EtOH 
(vehicle) or 10 nM Mib, DHT, P4, MPA, NET-A, LNG or NES, in the absence and presence of (A-B) 10 µM 
OHF, (C-D) 1 µM RU486 or (E-F) 1 µM ICI, for 72 hours. The medium was aspirated and cells were re-
treated for an additional 44 hours. Cell proliferation was measured using the MTT cell viability assay. Results 
are represented as fold proliferation relative to the vehicle control. The results shown are the averages (± SEM) 
of at least three independent experiments with each condition performed in triplicate. Statistical analysis was 
performed using two-way ANOVA with Bonferroni’s (compares all pairs of columns) as post-test. 
 
3.5 Androgens increase ERβ mRNA expression in both MCF-7 BUS and T47D breast 
cancer cells. 
It has recently been shown that the synthetic androgen, Mib, and the natural androgen, DHT, increase 
ERβ expression to the same extent as each other in MCF-7 breast cancer cells, via a mechanism 
requiring the AR (Rizza et al., 2014). We thus validated these findings in the MCF-7 BUS cell line, 
which is a clone of the MCF-7 breast cancer cell line that is more estrogen-sensitive (Villalobos et 
al., 1995). Real-time qPCR results in Figure 3.6A confirm that both Mib and DHT increase ERβ 
mRNA expression in MCF-7 BUS breast cancer cells, albeit to different extents. To exclude the 
possibility of cell-specific effects, we repeated the experiment in T47D breast cancer cells and 
showed that Mib and DHT also upregulated ERβ mRNA expression to different extents in these cells 
(Figure 3.6B). However, DHT increased ERβ mRNA expression to a greater extent than Mib in the 
T47D cells, while the reverse is true in the MCF-7 BUS cells (Figure 3.6C). In order to confirm that 
the effects of the androgens were via the AR, MCF-7 BUS cells were treated with Mib and DHT, in 
the absence and presence of the AR antagonist, OHF. Surprisingly, although we had detected ERβ 
mRNA expression in two biological replicate experiments in both the MCF-7 BUS (Figure 3.6A) and 
T47D (Figure 3.6B) cells, we were unable to reproduce these results when performing the 
experiments with the antagonist. Thus, we could not establish the role of the AR in mediating the 
effects of Mib and DHT on ERβ mRNA expression. Investigations into effects on ERβ protein 
expression in these cell lines could thus also not be performed. 
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Figure 3.6. Mib and DHT differentially increase ERβ mRNA expression in MCF-7 BUS and T47D breast 
cancer cells. The human (A) MCF-7 BUS and (B) T47D breast cancer cells were treated with either 0.1% 
(v/v) EtOH (vehicle), 10 nM Mib or DHT for 24 hours. Total RNA was isolated, cDNA synthesized, and ERβ 
and GAPDH mRNA expression analyzed using real-time qPCR. Results shown are the averages (±SD) of two 
independent experiments. The ratio of ERβ to GAPDH mRNA expression of the treated samples was 
calculated relative to that of the vehicle control. (C) The data from (A) and (B) were re-plotted to directly 
compare the androgen-induced effects between the MCF-7 BUS and T47D cell lines. Statistical analysis was 
performed using (A, B) one-way ANOVA with Newman-Keuls (compares all columns to each other) as post-
test or (C) two-way ANOVA with Bonferroni’s (compares all pairs of columns) as post-test. 
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3.6 While Mib and DHT decrease ERα mRNA expression via the AR in MCF-7 BUS 
breast cancer cells, the NET-A-induced decrease in ERα expression does not require the 
AR. 
Having confirmed that both Mib and DHT increase ERβ mRNA expression in both the MCF-7 BUS 
and T47D breast cancer cells, albeit to different extents, we next investigated whether these androgens 
would elicit similar effects on ERα expression in the MCF-7 BUS cell line. The cells were thus treated 
as described in Section 3.5, and real-time qPCR results show that both Mib and DHT significantly 
decreased ERα mRNA expression (Figure 3.7A). The addition of AR antagonist, OHF, reversed the 
effects of both Mib and DHT (Figure 3.7B), indicating that the Mib- and DHT-induced decrease in 
ERα mRNA expression is mediated by the AR. Western blot analysis of lysates from MCF-7 BUS 
cells treated as above, showed that Mib and DHT had no effect on ERα protein expression (Figure 
3.7D).  
 
Considering that Mib and DHT decreased ERα mRNA expression via the AR, we next investigated 
whether progestins with androgenic properties similar to DHT would elicit similar effects. Results 
show that NET-A downregulated both the mRNA (Figure 3.8A) and protein (Figure 3.8D) expression 
of ERα, while MPA and LNG had no effect. However, the addition of the AR antagonist, OHF, did 
not decrease the effects of NET-A on ERα mRNA (Figure 3.8B) or protein (Figure 3.8E) expression, 
suggesting that the AR is not involved. NES and NOMAC had no effect on ERα mRNA (Figure 
3.8A) or protein (Figure 3.8D) expression. Results also show that P4 decreased ERα mRNA 
expression (Figure 3.8A), while having no effect on ERα protein expression (Figure 3.8D). Given the 
anti-androgenic properties of P4 (Africander et al., 2014; Louw-du Toit et al., 2017a), it is surprising 
that the results in the presence of OHF show that, like the androgens, P4 decreased ERα mRNA 
expression via a mechanism requiring the AR (Figure 3.8B). 
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Figure 3.7. Mib and DHT decreased ERα mRNA expression via an AR-mediated mechanism in MCF-7 
BUS cells, while having no effect on ERα protein expression. The human MCF-7 BUS breast cancer cells 
were treated for 24 hours with either 0.2% (v/v) EtOH (vehicle), 10 nM Mib or DHT, in the absence and 
presence of 10 µM OHF. (A, B) Total RNA was isolated, cDNA synthesized, and ERα and GAPDH mRNA 
expression analyzed using real-time qPCR. The ratio of ERα to GAPDH mRNA expression of the treated 
samples was calculated relative to that of the vehicle control. (C, D) Protein lysates were analyzed by western 
blotting using primary antibodies specific for ERα and GAPDH (loading control). HEK-293 cells transiently 
transfected with an expression vector for ERα was used as a positive control, while untransfected COS-1 cells 
were used as a negative control. (C) A representative western blot is shown. (D) ERα protein expression was 
quantified using the MyImageAnalysis™ software, and normalized to GAPDH expression. Results shown for 
qPCR and western blotting are the averages (± SEM) of at least three independent experiments. Statistical 
analysis was performed using (A, D) one-way ANOVA with Newman-Keuls (compares all columns to each 
other) as post-test or (B) two-way ANOVA with Bonferroni’s (compares all pairs of columns) as post-test. 
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Figure 3.8 legend on next page.
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Figure 3.8. Only NET-A downregulates both ERα mRNA and protein expression. MCF-7 BUS cells were 
treated for 24 hours with either 0.2% (v/v) EtOH (vehicle) or 10 nM Mib, DHT, P4, MPA, NET-A, LNG, NES, 
or NOMAC, in the (A, D) absence and (B, E) presence of 10 µM OHF. (A, B) Total RNA was isolated, cDNA 
synthesized, and ERα and GAPDH mRNA expression analyzed using real-time qPCR. (C, D, E) Protein lysates 
were analyzed by western blotting using primary antibodies specific for ERα and GAPDH (loading control). 
HEK-293 cells transiently transfected with an expression vector for ERα was used as a positive control, while 
untransfected COS-1 cells were used as a negative control. (C) A representative western blot is shown. (D, E) 
ERα protein expression was quantified using the MyImageAnalysis™ software, and normalized to GAPDH 
expression. Results shown for qPCR and western blotting are the averages (± SEM) of at least three 
independent experiments. The ratio of ERα to GAPDH mRNA and protein expression is shown relative to the 
vehicle control. Statistical analysis was performed using (A, D) one-way ANOVA with Dunnett’s (compares 
all columns vs. control column) as post-test or (B, E) two-way ANOVA with Bonferroni’s (compares all pairs 
of columns) as post-test. 
 
3.7 The MDA-MB-453 TNBC cell line expresses endogenous ERβ and AR. 
Given that we were unable to detect ERβ mRNA in the MCF-7 BUS and T47D cells, we next used 
the MDA-MB-453 breast cancer cell line, a model system commonly used to investigate AR 
mechanisms in triple negative breast cancer (TNBC) (Hall et al., 1994). Western blot analysis showed 
that the MDA-MB-453 cell line expresses the AR, GR and ERβ, but not PR-A, PR-B or ERα (Figure 
3.9), suggesting that it is suitable model for investigating AR-mediated effects on ERβ (Vranic et al., 
2011).  
 
However, as it is known that these cells express an AR with a point mutation in its LBD that has been 
shown to have reduced sensitivity to DHT and MPA in transactivation assays (Moore et al. 2012a), 
we investigated whether the progestogens would protect the mutant AR from degradation as was 
observed for the wild-type AR in the MCF-7 BUS cells (Figure 3.2). Western blot analysis showed 
that the androgens increase the protein levels of the mutant AR in the MDA-MB-453 cells, while the 
progestins had no effect (Figure 3.10B). Furthermore, results in Figure 3.10C show that the AR 
antagonist, OHF, inhibits the effects of Mib and DHT, while having no influence on the effects of the 
progestogens.  
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Figure 3.9. The MDA-MB-453 TNBC cell line expresses endogenous ERβ and AR. Whole cell extracts 
were prepared from MDA-MB-453 breast cancer cells and analyzed by western blotting using primary 
antibodies specific for PR-A/B, AR, GR, ERα, ERβ and GAPDH (loading control). COS-1 cells transiently 
transfected with expression vectors for either PR-A, PR-B or GR, or HEK-293 cells transiently transfected 
with expression vectors for either the AR, ERα or ERβ, were used as positive controls. Untransfected COS-1 
or HEK-293 cells were used as negative controls. A representative western blot of at least three independent 
experiments is shown.  
 
3.8 Androgens increase ERβ mRNA expression in MDA-MB-453 breast cancer cells. 
Considering that our results show that the MDA-MB-453 cell line expresses endogenous ERβ and 
AR, we next investigated whether ERβ mRNA and protein expression could be regulated by the 
androgens in the MDA-MB-453 breast cancer cell line. The results in Figure 3.11 showing that both 
Mib and DHT increased ERβ mRNA expression (Figure 3.11A) via the AR (Figure 3.11B), are 
consistent with the study by Rizza et al. (2014). We were unable to establish whether these androgens 
also increased ERβ protein expression, as the commercial ERβ antibody from Abcam (EPR3777) 
previously used to detect ERβ (Figure 3.4 and Figure 3.9) was discontinued. Western blot analysis 
using an alternate commercial ERβ antibody from Abcam (EPR20743) indicated that this antibody 
was not specific for ERβ, as a band of the same size as the ERβ protein was observed in the negative 
control (Figure B4, Addendum B). It is noteworthy that this new ERβ antibody (EPR20743) has 
subsequently also been discontinued.  
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Figure 3.10. Both androgens induce stabilization of the endogenous mutant AR in the MDA-MB-453 
breast cancer cell line. The human MDA-MB-453 breast cancer cells were treated for 24 hours with either 
0.2% (v/v) EtOH (vehicle), or 10 nM Mib, DHT, P4, MPA, NET-A, LNG, NES or NOMAC, in the absence 
and presence of 10 µM OHF. Protein lysates were analyzed by western blotting using primary antibodies 
specific for the AR and GAPDH (loading control). HEK-293 cells transiently transfected with an expression 
vector for the AR was used as a positive control, while untransfected COS-1 cells were used as a negative 
control. (A) A representative western blot of at least three independent experiments is shown. (B, C) AR 
protein expression was quantified using the MyImageAnalysis™ software, and normalized to GAPDH 
expression. Results shown are the averages (± SEM) of at least three independent experiments. The ratio of 
AR to GAPDH protein expression is shown relative to the vehicle control. Statistical analysis was performed 
using (B) one-way ANOVA with Dunnett’s (compares all columns vs. control column) as post-test or (C) two-
way ANOVA with Bonferroni’s (compares all pairs of columns) as post-test. 
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Figure 3.11. Mib and DHT differentially increased ERβ mRNA expression via the AR in MDA-MB-453 
breast cancer cells. The human MDA-MB-453 cells were treated for 24 hours with either 0.2% (v/v) EtOH 
(vehicle), 10 nM Mib or DHT, in the absence and presence of 10 µM OHF. Total RNA was isolated, cDNA 
synthesized, and ERβ and GAPDH mRNA expression analyzed using real-time qPCR. Results shown are the 
averages (± SEM) of at least three independent experiments. The ratio of ERβ to GAPDH mRNA expression 
is shown relative to the vehicle control. Statistical analysis was performed using (A) one-way ANOVA with 
Newman-Keuls (compares all columns to each other) as post-test or (B) two-way ANOVA with Bonferroni’s 
(compares all pairs of columns) as post-test. 
 
3.9 Like Mib and DHT, the androgenic progestins increase ERβ mRNA expression 
in MDA-MB-453 cells via an AR-mediated mechanism. 
Next, we investigated whether progestins with androgenic properties, would increase ERβ mRNA 
expression in the MDA-MB-453 cells. Real-time qPCR results show that MPA and NET-A increased 
ERβ mRNA expression to the same extent as each other and DHT, while LNG increased expression 
to a greater extent than both Mib and DHT (Figure 3.12A). Results in Figure 3.12B show that the 
addition of the AR antagonist OHF reversed the MPA-, NET-A-, and LNG-induced effects on ERβ 
mRNA expression, suggesting that these progestins regulate ERβ mRNA expression via a mechanism 
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involving the AR. In contrast, NES and NOMAC, which display anti-androgenic properties similar 
to P4, had no effect on ERβ mRNA expression (Figure 3.12A), while P4 downregulated the expression 
(Figure 3.12A). However, unlike the results observed for P4 on ERα mRNA expression, the AR was 
not required for the effects of P4 on ERβ mRNA expression (Figure 3.12B). Due to the lack of a 
commercial antibody specific to ERβ, we were unable to evaluate the effects of the progestogens on 
ERβ protein expression.  
   
 
  
 
Figure 3.12. MPA, NET-A and LNG, like the androgens, upregulate ERβ mRNA expression via an AR-
mediated mechanism in MDA-MB-453 cells. The human MDA-MB-453 cell line was treated for 24 hours 
with either 0.2% (v/v) EtOH (vehicle) or 10 nM Mib, DHT, P4, MPA, NET-A, LNG, NES, or NOMAC, in the 
absence and presence of 10 µM OHF. Total RNA was isolated, cDNA synthesized, and ERβ and GAPDH 
mRNA expression analyzed using real-time qPCR. Results shown are the averages (± SEM) of at least three 
independent experiments. The ratio of ERβ to GAPDH mRNA expression is shown relative to the vehicle 
control.  Statistical analysis was performed using (A) one-way ANOVA with Newman-Keuls (compares all 
columns to each other) as post-test or (B) two-way ANOVA with Bonferroni’s (compares all pairs of columns) 
as post-test. 
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3.10 DHT decreases E2-induced proliferation of the MDA-MB-453 breast cancer cell 
line when ERα and ERβ are co-expressed. 
Given that the MDA-MB-453 cell line expresses ERβ and the AR, we next evaluated proliferation of 
these cells in response to E2, in the absence and presence of DHT. Results from the MTT cell viability 
assay show that E2 dose-dependently increased MDA-MB-453 breast cancer cell proliferation, and 
that DHT had no effect on the E2-induced proliferation (Figure 3.13A). As it has previously been 
shown that DHT inhibits E2-induced proliferation in MCF-7 breast cancer cells expressing both ERα 
and ERβ (Ando et al., 2002), we next transiently transfected the MDA-MB-453 cells with an 
expression vector encoding the human ERα. The results in Figure 3.13C show that DHT decreased 
the E2-induced proliferation of the MDA-MB-453 cells co-expressing ERα and ERβ. This decrease 
appeared to be more pronounced in cells transiently transfected with both ERα and ERβ (Figure 
3.13E). Results from similar experiments conducted with the progestins were inconclusive as the E2 
control did not cause proliferation in this experiment (data not shown). Importantly, these results are 
from a single experiment performed in triplicate and should be repeated to determine the statistical 
significance of the findings. 
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Figure 3.13. E2-induced proliferation of MDA-MB-453 breast cancer cells is decreased in the presence 
of DHT when ERα and ERβ are co-expressed. The human MDA-MB-453 breast cancer cells were either 
(A) untransfected, or transiently transfected with an expression vector for human ERα in the (C) absence and 
(E) presence of an expression vector for human ERβ. All cells were treated for 72 hours with either 0.2% (v/v) 
EtOH (vehicle) or increasing concentrations of E2, in the absence and presence of equimolar concentrations of 
DHT. The medium was aspirated and cells were re-treated for an additional 44 hours. Cell proliferation was 
measured using the MTT cell viability assay. Results are represented as fold proliferation relative to the vehicle 
control. The results shown are the averages (± SD) of a single experiment with each condition performed in 
triplicate. (B, D, F) The data from (A), (C) and (E) were re-plotted to show the statistical significance between 
either E2 vs. E2 plus DHT, or over-expressed ERα and endogenous ERβ vs. over-expressed ERα and over-
expressed ERβ. Statistical analysis was performed using two-way ANOVA with Bonferroni’s (compares all 
pairs of columns) as post-test.
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4.1 Introduction 
Multiple steroid receptors play a role in breast cancer pathogenesis and often influence each other’s 
activity (reviewed in (Sikora 2016)). For example, ERβ decreases breast cancer cell growth by 
inhibiting the activity of ERα when the ER subtypes are co-expressed, while ERβ mimics the 
proliferative effects of ERα in ERα-negative breast cancer (Leygue et al., 1998; Dotzlaw et al., 1999; 
Speirs et al., 1999; Williams et al., 2008; Zhao et al., 2008; Hartman et al., 2009; Leygue and Murphy, 
2013). Similarly, the AR, which is most frequently co-expressed with ERα in breast cancer (Agoff et 
al., 2003; Niemeier et al., 2010; Tsang et al., 2014), has also been shown to decrease breast cancer 
cell growth in ER-positive breast cancer (Peters et al., 2009; Rizza et al., 2014). At least two 
mechanisms have been reported for this inhibitory role of the AR in ER-positive breast cancer (Peters 
et al., 2009; Rizza et al., 2014). One mechanism is that the androgen-bound AR competes with ERα 
for binding to EREs in ER target genes (Peters et al., 2009). A second mechanism is that the androgen-
activated AR binds to an ARE in the ERβ gene promoter, resulting in increased expression of the 
anti-proliferative ERβ (Rizza et al., 2014). Interestingly, inhibition of ERα transcriptional activity has 
also been shown when the AR was activated by the first generation progestin, MPA (Peters et al., 
2009). However, MPA has also been shown to promote the development of breast cancer by a 
mechanism involving the disruption of normal androgen signaling (Carroll et al., 2016). In fact, other 
progestins commonly used in contraception and menopausal HT, such as NET-A and LNG, have also 
been shown to increase breast cancer risk (Rossouw et al., 2002; Beral et al., 2003; Fournier et al., 
2008). Although progestins were designed to mimic the activity of P4 by binding to the PR, many 
progestins elicit off-target biological effects by binding to other steroid receptors (Hapgood et al. 
2004; Sitruk-Ware 2006; Africander et al. 2011a; Stanczyk et al. 2013). Particularly relevant to this 
thesis is the fact that some progestins bind to the AR, and either elicit androgenic properties similar 
to the natural androgen, DHT, or anti-androgenic properties similar to the natural progestogen, P4 
(Africander et al. 2014; Louw-du Toit et al. 2017a). The question that arises is whether progestins 
displaying androgenic properties activate the AR by a similar mechanism as DHT, and whether these 
progestins, like DHT, would increase ERβ expression. Whether the androgen- or progestin-activated 
AR also modulates ERα expression is not known. In Chapter 3, we thus addressed these questions by 
investigating the ability of the progestins to either induce the AR N/C interaction or inhibit the DHT-
induced N/C interaction. Effects of the progestins, relative to each other, P4, DHT and the synthetic 
androgen Mib, on ERα and ERβ expression, as well as breast cancer cell proliferation, was also 
investigated. 
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4.2 Progestins binding to the AR elicit different conformations in the receptor. 
It is well-known that the conformation induced in a steroid receptor by a particular ligand contributes 
to the biological activity of that ligand (Griekspoor et al., 2007). For the AR, it was previously thought 
that all AR agonists induce the N/C interaction, while AR antagonists inhibit the androgen-induced 
AR N/C interaction (Langley et al., 1995). However, our group and others have shown that although 
MPA and NET-A elicit similar agonist activity to DHT (Africander et al. 2014; Louw-du Toit et al. 
2017a), MPA does not induce the AR N/C interaction, while DHT and NET-A do (Kemppainen et 
al., 1999; Tanner, 2002; Africander et al., 2014). It was thus suggested that MPA and NET-A activate 
the AR by inducing different conformations in the receptor (Africander et al., 2014). The first aim of 
this thesis was thus to investigate the ability of selected progestins to induce the AR N/C interaction, 
or antagonize the DHT-induced AR N/C interaction, as a measure of receptor conformation (Section 
3.1). The results in Figure 3.1A showing that P4 and MPA do not induce the AR N/C interaction, 
while NET-A does, are consistent with a previous study from our group (Africander et al., 2014). 
The lack of AR N/C interaction with MPA is possibly due to the fact that this first generation 
progestin is a 17α-hydroxyprogesterone derivative (Schindler et al., 2003) that is more structurally 
related to P4 (Schindler et al., 2003). Similarly, NES and NOMAC, which are 19-norpregnane 
progestins that are also structurally related to P4 (Schindler et al., 2003), did not induce the AR N/C 
interaction (Figure 3.1A). In addition, the spironolactone derivative, DRSP, previously shown to have 
a similar biochemical profile as P4 (Krattenmacher, 2000), also did not induce the AR N/C interaction. 
We show for the first time that LNG and GES induce the AR N/C interaction to the same extent as 
each other and NET-A, suggesting that these progestins activate the AR by a similar mechanism as 
NET-A (Figure 3.1A). This may be due to the fact that these progestins are all 19-nortestosterone 
derivatives, which are structurally related to the natural androgen, testosterone (Schindler et al., 
2003). The fact that NET-A, LNG and GES have previously been shown to display similar potencies 
and efficacies as DHT, but do not induce the AR N/C interaction to the same extent as DHT, 
underlines the fact that the N/C interaction does not predict ligand potency and efficacy for 
transactivation (Africander et al., 2014). Taken together, these results are in agreement with previous 
reports that structural differences between ligands can lead to differences in receptor conformation 
(Kuil et al., 1995). 
 
When investigating whether progestins could antagonize the DHT-induced AR N/C interaction, the 
results showed that, P4, NES, NOMAC and DRSP do not antagonize the AR N/C interaction induced 
by DHT (Figure 3.1B). Interestingly, P4 has previously been shown to inhibit the DHT-induced AR 
N/C interaction (Kemppainen et al., 1999). It is possible that the difference between our results and 
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that of Kemppainen and co-workers can be ascribed to the use of different experimental conditions. 
For example, hormones are known to elicit cell-specific effects (reviewed in (Katzenellenbogen et al. 
1996)), and Kemppainen et al. (1999) used the Chinese hamster ovary (CHO) cell line as an in vitro 
model system, while we used COS-1 African monkey kidney fibroblast cells. In addition, we used 
the pTAT-GRE-E1b-luc luciferase reporter construct that has two copies of the GRE (Sui et al., 
1999), while Kemppainen used the G5E1b-luc construct that has five copies of the GRE (Lillie and 
Green, 1989). Consistent with a previous study (Tanner, 2002), our results showed that MPA, but not 
NET-A, repressed the DHT-induced AR N/C interaction (Figure 3.1B). This result suggests that 
inhibition of the androgen-induced AR N/C interaction does not imply AR antagonist activity. As 
expected, like NET-A, LNG and GES, did not repress the DHT-induced AR N/C interaction, 
suggesting that LNG and GES elicit similar conformations in the AR as NET-A. Taken together, our 
results showed that the AR N/C interaction is not induced by all AR agonists, nor is the DHT-induced 
N/C interaction inhibited by all AR antagonists. Importantly, the mammalian two-hybrid assay does 
not include the full-length human AR, nor does it take into account the conformational changes 
induced in the receptor by its interaction with DNA and other proteins of the transcription machinery 
(Griekspoor et al., 2007; Africander et al., 2014). Thus, the results from this in vitro mammalian two-
hybrid assay may not reflect the progestogen-induced AR conformation in vivo. 
 
4.3 Progestogens do not influence AR protein levels in MCF-7 BUS breast cancer 
cells. 
The evidence in the literature suggests that the stability of the AR protein is increased by the binding 
of androgens, while anti-androgens cause AR protein degradation (Kemppainen et al., 1992; Zhou et 
al., 1995; Greeve et al., 2004). We therefore investigated whether progestins displaying androgenic 
activity would stabilize the AR protein in the MCF-7 BUS cells in a similar manner as previously 
reported for the synthetic androgen Mib and the natural androgen DHT (Ando et al., 2002; Greeve et 
al., 2004; Macedo et al., 2006). Both Mib and DHT increased AR protein levels (Figure 3.2B), 
suggesting that the androgens stabilize the AR. In contrast, P4 and the progestins that can bind to the 
AR do not cause degradation of the AR, suggesting that these ligands induce a conformation in the 
AR LBD that protects it from being degraded (Kemppainen et al., 1999; de Jésus-Tran et al., 2006).  
Importantly, it has previously been shown that the AR is required for the effects of MPA in breast 
cancer therapy (Birrell et al. 1995a), and a reduction in AR protein levels has been shown to 
contribute to the failure of MPA therapy in breast cancer tumours (Buchanan et al., 2005). The fact 
that neither MPA, nor NET-A or LNG, decreased AR protein levels in our experimental systems, 
suggest that these progestins may in fact be effective in breast cancer therapy. However, these results 
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need to be interpreted with caution as MPA, NET-A and LNG have all been associated with increased 
risk of breast cancer. 
 
4.4 The MPA-, NET-A- and LNG-induced increase in T47D human breast cancer 
cell proliferation requires multiple steroid receptors. 
Numerous experimental studies have investigated the effects of the androgens and progestins on 
breast cancer cell proliferation, but the results are often contradictory. The latter may be due to factors 
such as intra-laboratory cell line heterogeneity or phenotypic drift (Burdall et al., 2003), or the fact 
that few studies directly compare the effects of these hormones in the same model system. We thus 
directly compared the effects of selected progestins relative to each other, P4 and the androgens, Mib 
and DHT, on proliferation of the commonly used MCF-7 BUS and T47D breast cancer cell lines. Our 
results showing that Mib and DHT increased proliferation of both these cell lines (Figure 3.3) are 
consistent with some studies (Hackenberg et al. 1988; Birrell et al. 1995b; Baniwal et al. 2011), but 
not others showing inhibition of proliferation of the MCF-7 and T47D breast cancer cell lines (Birrell 
et al. 1995b; Ando et al. 2002; Aspinall et al. 2004; Peters et al. 2009; Lanzino et al. 2013; Rizza et 
al. 2014). Similarly, our result showing that P4 and the selected progestins increased proliferation of 
both MCF-7 BUS and T47D breast cancer cell lines (Figure 3.3) are in agreement with numerous 
other studies (Jeng and Jordan, 1991; Van Der Burg et al., 1992; Jeng et al., 1992; Catherino et al., 
1993; Cappelletti et al., 1995; Schoonen et al., 1995a, 1995b; Franke and Vermes, 2003; Liang et al., 
2006; Giulianelli et al., 2012; Ruan et al., 2012), but in contrast to other studies (Jeng and Jordan, 
1991; Jeng et al., 1992; Botella et al., 1994; Formby and Wiley, 1998; Wiebe et al., 2000; Ruan et 
al., 2012). Discrepancies in responses between the various studies may be due to the use of different 
cell lines, such as the T47D vs. MCF-7 vs. the MCF-7 BUS cells or different concentrations of 
progestins used (reviewed in (Moore et al. 2012b)). 
 
Progestins elicit their biological effects by binding to the PR but also other members of the steroid 
receptor family (reviewed in (Africander et al. 2011a)). As some progestins bind to multiple steroid 
receptors, we investigated the role of the AR, PR, GR and ER, which are all endogenously expressed 
in both the MCF-7 BUS and T47D cells (Figure 3.4) (Horwitz et al., 1975, 1978; Vladusic et al., 
2000; Singer et al., 2003). Considering that Bical, a well-known antagonist of androgen effects via 
the AR, did not reverse the effects of the androgens on cell proliferation in T47D cells (Figure B6, 
Addendum B), we used the AR antagonist, OHF, instead. In the MCF-7 BUS cells, our results showed 
that the AR was required for the effects of MPA, NET-A and LNG (Figure 3.5A). However, using 
RU486, a well-known PR, GR but also AR antagonist (Spitz and Bardin, 1993; Africander et al., 
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2014), we could not draw any conclusions about the role of the PR or GR in these cells. This was due 
to the fact that RU486 did not antagonize the effects of the GR-specific agonist, Dex, or PR-specific 
agonist, R5020, while also increasing proliferation. These results suggest that RU486 acts as an 
agonist, rather than an antagonist in the MCF-7 BUS cells (Figure B2, Addendum B). It has 
previously been reported that RU486 acts as an agonist in some cells, while it is an antagonist in 
others (Catherino et al., 1993; Spitz and Bardin, 1993; Kalkhoven et al., 1994). The role of the ER in 
the MCF-7 BUS cells could also not be investigated as 1 µM ICI significantly decreased the viability 
of the MCF-7 BUS cells (Figure B3, Addendum B), suggesting that this concentration of ICI may be 
cytotoxic to these cells.  
 
In the T47D cells, both the AR (Figure 3.5B) and PR (Figure 3.5D) were shown to be required for 
the effects of MPA, NET-A and LNG, while the ER was required for the effects of NET-A and LNG 
(Figure 3.5F). RU486 did not inhibit effects of the GR-specific agonist, Dex, in the T47D cells, 
suggesting that it cannot act as an antagonist of the GR in this cell line (Figure B2, Addendum B). 
RU486 is known to act as either an agonist or an antagonist, depending on receptor density (Zhao et 
al., 2003). No conclusions could thus be drawn about the role of the GR in the responses of MPA, 
NET-A and LNG. However, as it is well-known that MPA is an agonist of the GR, while NET-A and 
LNG are not (Koubovec et al. 2005; Africander et al. 2011b; Stanczyk et al. 2013), one could 
speculate that MPA may increase proliferation of the T47D or MCF-7 BUS cells via the GR. 
Nonetheless, these results suggest that multiple steroid receptors are required for the effects of MPA, 
NET-A and LNG on T47D breast cancer cell proliferation. It is noteworthy that at least one other 
study has previously shown that the proliferative effects of LNG occurs via the ER in MCF-7 breast 
cancer cells (Catherino et al., 1993). Although ICI is an antagonist of both ERα and ERβ, it is likely 
that the proliferative effects of NET-A and LNG are via ERα as both these progestins have been 
shown to bind to ERα, but not ERβ ( Louw-du Toit et al. 2017a). Considering that the T47D cells 
express higher PR levels than the MCF-7 cells (Janowski et al., 2006), it is not surprising that this 
steroid receptor was required for progestogen-induced proliferation. Considering that progestins were 
designed to act via the PR (Sitruk-Ware, 2006), it is likely that the PR may in fact also be required 
for the progestogen-induced proliferation in the MCF-7 BUS cells. Taken together, we showed that 
the AR, PR and ER are required for the effects of MPA, NET-A and LNG in the T47D cell line, while 
only the AR was required for their effects in the MCF-7 BUS cell line. 
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4.5 Mib and DHT differentially increase ERβ mRNA expression in MCF-7 BUS and 
T47D breast cancer cells. 
A recent study by Rizza et al. (2014) was the first to show that Mib and DHT both increased the 
expression of ERβ mRNA and protein in MCF-7 breast cancer cells via a mechanism involving the 
AR. We validated these findings on mRNA expression in the human MCF-7 BUS breast cancer cells, 
which is a clone of the MCF-7 breast cancer cell line that is more estrogen-sensitive (Villalobos et 
al., 1995), as well as the human T47D cell line. Subsequent to two biological replicate experiments 
showing that both Mib and DHT increased ERβ mRNA expression in the MCF-7 BUS (Figure 3.6A) 
and T47D (Figure 3.6B) breast cancer cell lines, we were unable to reproduce the above-mentioned 
results. Therefore, neither the role of the AR in mediating these responses on ERβ mRNA expression, 
nor effects on ERβ protein expression, could be detected. The exact reason for the inability to detect 
ERβ mRNA in these cell lines in subsequent experiments is not clear. However, at least one study 
has reported that ER levels in MCF-7 cells can vary between experiments (Osborne et al., 1987). 
Furthermore, it has previously been reported that human breast cancer cell lines are prone to 
phenotypic drift, which may result in loss of steroid receptor expression when cells undergo more 
than ten passages (Wistuba et al., 1998; Masters, 2000). Thus, as the MCF-7 BUS and T47D breast 
cancer cell lines used in this thesis were passaged up to thirty-five times, it is likely that the expression 
of ERβ may have been lost (reviewed in (Masters 2000)).  
 
4.6 Androgens decrease ERα mRNA via the AR in the MCF-7 BUS breast cancer cell 
line. 
The study by Rizza et al. (2014) investigated androgen effects on only ERβ expression. Considering 
that ERα and ERβ play opposing roles in breast cancer (Kuiper et al., 1996; Leygue et al., 1998; 
Dotzlaw et al., 1999; Speirs et al., 1999; Zhao et al., 2008; Leygue and Murphy, 2013), it is important 
to also investigate the effects of Mib and DHT on ERα expression. One study, more than 20 years 
ago, showed that prolonged exposure (i.e. up to 14 days) to 10 nM DHT caused downregulation of 
ERα mRNA and protein expression via the AR in the ZR-75-1 human breast cancer cell line  (Poulin 
et al., 1989). Interestingly, this cell line is known to express higher levels of AR than the MCF-7 
breast cancer cell line (Birrell et al. 1995b). As it is well-known that hormones can elicit cell-specific 
effects (reviewed in (Katzenellenbogen et al. 1996)), we next investigated the effects of Mib and 
DHT on ERα expression in the same in vitro model system as for ERβ expression, namely the MCF-
7 BUS breast cancer cell line. Consistent with the study by Poulin et al. (1989), our results showed 
that the natural androgen, DHT, as well as the synthetic androgen, Mib, significantly decreased ERα 
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mRNA expression (Figure 3.7A) via the AR (Figure 3.7B). However, the result showing that Mib 
and DHT had no effect on ERα protein expression in the MCF-7 BUS cells (Figure 3.7D) is in contrast 
to the effects shown in the ZR-75-1 cell line (Poulin et al., 1989). The discordance of our results 
between ERα mRNA and protein expression suggests that post-translational modifications may have 
occurred in the MCF-7 BUS cell line, as previously suggested by Liu and co-workers (Liu et al., 
2016). Although the precise mechanism whereby the AR downregulates ERα mRNA expression is 
not known, it may be that the Mib- and DHT-activated AR decrease ERα mRNA expression via the 
ERα tethering to DNA-bound transcription factors like AP-1 (McDonnell and Norris, 2002). This is 
likely as both Mib and DHT have been shown to repress an AP-1-luc reporter construct via the AR 
(Africander et al. 2014; Louw-du Toit et al. 2017a), and it is known that AP-1 cis-elements are found 
in the promoter of the ERα gene (Carroll et al., 2006).  
 
When investigating the effects of the androgenic progestins on ERα expression, we showed that NET-
A decreased ERα mRNA and protein expression, while MPA and LNG had no effect (Figure 3.8A 
and D). In contrast to the effects of Mib and DHT on the mRNA expression of ERα, our results 
showed that the effect of NET-A on ERα mRNA (Figure 3.8B) and protein (Figure 3.8E) expression 
was not via the AR. This result was unexpected as we had previously shown that the AR is required 
for the effects of NET-A on cell proliferation (Figure 3.5A and Figure 3.5B). Although NET-A has 
been shown to bind to ERα, it displays a much lower affinity for ERα than the AR (Louw-du Toit et 
al. 2017a). Thus, it is unlikely that NET-A will elicit its physiological effects via ERα in a system 
where both ERα and the AR are expressed. Much to our surprise, our results showed that P4 
downregulated ERα mRNA expression (Figure 3.8A) via the AR (Figure 3.8E). This result is hard to 
interpret as P4 is an antagonist for AR transactivation via an ARE, but is a partial agonist for AR 
transrepression via either AP-1 or NFκB-luc reporter plasmids (Africander et al. 2014; Louw-du Toit 
et al. 2017a). Thus, it is likely that the P4-bound AR could decrease ERα mRNA expression via a 
similar tethering mechanism as suggested above for Mib and DHT. 
 
4.7 Androgens as well as progestins with androgenic properties increase ERβ mRNA 
expression via an AR-mediated mechanism in the human MDA-MB-453 breast cancer 
cell line. 
As we were unable to detect ERβ mRNA in the MCF-7 BUS and T47D cells, an alternative in vitro 
model system was required for the investigation into the effects of the androgenic hormones on ERβ 
expression. Thus, the MDA-MB-453 human breast cancer cells, a cell line commonly used to 
investigate AR mechanisms in TNBC (Hall et al., 1994), was characterized in terms of steroid 
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receptor expression. Our results confirmed previous reports that this cell line expresses endogenous 
AR, GR and ERβ, but not PR-A, PR-B or ERα (Figure 3.9) (Hall et al. 1994; Al-Bader et al. 2011; 
Vranic et al. 2011; Moore et al. 2012a; Barton et al. 2017). It is noteworthy that this cell line expresses 
a mutant AR with a point-mutation in the LBD (Moore et al. 2012a). This mutant AR has been shown 
to have reduced sensitivity to DHT and MPA in transactivation assays (Moore et al. 2012a). While 
DHT has been shown to stabilize the mutant AR in the MDA-MB-453 breast cancer cells in a similar 
manner to the wild-type AR (Yeap et al., 1999; Ni et al., 2011), this has not been shown for MPA or 
any other progestins displaying androgenic properties.  Knowing that P4 and the selected progestins 
protect the wild-type AR from degradation in the MCF-7 BUS cells (Figure 3.2), effects on the mutant 
AR were also investigated. Consistent with our results for the wild-type AR in the MCF-7 BUS cells 
(Figure 3.2), we showed that neither P4 nor any of the progestins influenced the protein levels of the 
mutant AR (Figure 3.10B). Mib and DHT, however, increased the protein levels of the mutant AR in 
the MDA-MB-453 cells (Figure 3.10B), while the AR antagonist, OHF, reversed these effects (Figure 
3.10C). Taken together, our results showed that the androgens and progestins that bind to the AR had 
similar effects on the protein levels of the mutant and wild-type AR, suggesting that the point 
mutation in the LBD of the AR mutant expressed in the MDA-MB-453 cell line does not influence 
the activity of these hormones in this cell line. 
 
We next hypothesized that ERβ expression would be regulated by the androgens in the MDA-MB-
453 breast cancer cell line. Indeed, our results confirmed that both Mib and DHT increased ERβ 
mRNA expression (Figure 3.11A) via the AR (Figure 3.11B) in the MDA-MB-453 cells. MPA, NET-
A and LNG also increased ERβ mRNA expression (Figure 3.12A) via the AR (Figure 3.12B), while 
NES and NOMAC, which display anti-androgenic properties similar to P4, did not regulate ERβ 
mRNA expression (Figure 3.12A). LNG has previously been shown to bind to the AR with similar 
affinity as DHT, and display similar AR agonist potency for transactivation as DHT, MPA and NET-
A (Louw-du Toit et al. 2017a). Thus, it was a surprise that LNG increased ERβ mRNA expression to 
a greater extent than both Mib and DHT. Due to the unavailability of a reliable ERβ antibody, effects 
on ERβ protein expression could not be investigated. In fact, numerous studies have reported that 
multiple commonly used commercial ERβ antibodies greatly vary in sensitivity and specificity for 
this protein (Choi et al., 2001; Skliris et al., 2001; Carder et al., 2005; Weitsman et al., 2006; Wu et 
al., 2012; Andersson et al., 2017; Nelson et al., 2017). For example, Nelson and co-workers have 
shown that some ERβ antibodies detect either a band in ERβ-negative samples, implying non-
specificity, or additional non-specific proteins of the incorrect size, implying cross-reactivity with 
other proteins and reduced sensitivity for ERβ (Nelson et al., 2017). Moreover, it has been shown 
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that some commercial ERβ antibodies cross-react with ERα (Wu et al., 2012). The lack of a reliable 
commercially available ERβ antibody has prevented the evaluation of effects on ERβ protein 
expression in this study, and highlights the need for a reliable ERβ antibody to fully understand the 
role of ERβ in breast cancer. 
 
4.8 DHT decreases E2-induced proliferation of the MDA-MB-453 breast cancer cell 
line when ERα and ERβ are co-expressed. 
As mentioned in Section 4.6, ERα and ERβ, play differential roles in breast cancer, with ERα being 
the driver of proliferation, while the role of ERβ is dependent on whether ERα is expressed (Leygue 
et al., 1998; Dotzlaw et al., 1999; Speirs et al., 1999; Zhao et al., 2008). In the absence of ERα, ERβ 
has been shown to increase proliferation and mimic the effects of ERα, while ERβ antagonizes the 
proliferative effects of ERα when these receptors are co-expressed (Moore et al., 1988; O’Neill et al., 
2004; Skliris et al., 2006; Fox et al., 2008; Leygue and Murphy, 2013). As the MDA-MB-453 TNBC 
cells do not express ERα, the results in Figure 3.13A showing increased proliferation in the presence 
of E2, suggest that the proliferative response is via the endogenous ERβ. Interestingly, E2-induced 
proliferation was decreased when ERα and ERβ were co-expressed (Figure 3.13C and Figure B5, 
Addendum B), demonstrating that ERβ has a bi-faceted role in breast cancer cell proliferation. Our 
result showing that DHT decreased E2-induced proliferation of the MDA-MB-453 cells when the ER 
subtypes are co-expressed (Figure 3.13C) is consistent with a previous study (Ando et al., 2002). 
These authors showed that DHT inhibited the proliferation of MCF-7 human breast cancer cells in 
the absence and presence of E2, and that the effect required the AR (Ando et al., 2002). Thus, although 
we did not evaluate the role of the AR in the DHT-induced effect, it is likely that DHT elicits its 
growth inhibitory effects by activating the AR. In addition, the over-expression of ERβ appears to 
enhance the DHT-induced decrease in E2-mediated proliferation (Figure 3.13E). It can thus be 
speculated that an increase in ERβ mRNA expression by the androgen-activated AR may lead to anti-
proliferative effects in cells co-expressing ERα and ERβ. Similar effects may thus be observed with 
progestins displaying androgenic properties comparable to DHT, as our results have shown that all 
these compounds increased ERβ mRNA expression via the AR in MDA-MB-453 cells. However, as 
these results are from a single experiment with each condition performed in triplicate, these 
experiments need to be repeated before definitive conclusions can be made. 
 
4.9 Conclusion 
Although progestins were designed to mimic the biological activity of P4 by binding to the PR, the 
findings of this thesis, summarized in Table 4.1 and 4.2, highlight the fact that these compounds do 
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not always mimic the actions of P4 at a molecular level. In this thesis, the focus was on progestins 
that bind to the AR and elicit either androgenic activity like DHT, or anti-androgenic activity like P4. 
Our results showed that although MPA, NET-A and LNG are as potent and efficacious as DHT, these 
progestins do not necessarily activate the AR by the same mechanism as DHT. Nonetheless, like 
DHT, these three androgenic progestins increased ERβ mRNA expression via the AR in the MDA-
MB-453 breast cancer cell line. Although results could not be reproduced after two experiments, 
likely due to loss of ERβ expression due to high passage numbers, we showed that both Mib and DHT 
also increased ERβ mRNA expression in the ERα-positive MCF-7 BUS and T47D cells. It is thus 
possible that MPA, NET-A and LNG would also increase ERβ mRNA expression in ERα-positive 
breast cancer cells. While the Mib- and DHT-activated AR decreased ERα mRNA expression, MPA, 
NET-A and LNG did not influence ERα expression. The result showing downregulation of ERα 
mRNA expression by the androgen-activated AR suggests a third mechanism for the inhibitory role 
of the AR in ER-positive breast cancer. However, this mechanism is only true when the AR is 
activated by the classical androgens, and not when activated by progestins displaying androgenic 
properties. On the other hand, these results should be interpreted with caution as the AR-mediated 
effects of Mib and DHT, as well as MPA, NET-A and LNG, resulted in increased proliferation of the 
MCF-7 BUS and T47D cells. Taken together, the results of this study highlight not only the important 
roles of the AR and ERβ in breast cancer, but also that the role of progestins in breast cancer is not 
straightforward. Considering the complex and intertwined nature of steroid receptor signaling 
pathways in breast cancer, and the fact that some progestins activate multiple steroid receptors, it is 
important to unravel the mechanisms whereby progestins elicit their effects in breast cancer. 
Understanding these mechanisms may facilitate the design of new drugs for the treatment and 
prevention of AR- and ER-positive breast cancer.
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Table 4.1. Summary of the effects of androgens and progestogens on AR, ERβ and ERα expression. 
 
Androgens Androgenic progestins Anti-androgenic progestogens 
Mib DHT MPA NET-A LNG P4 NES NOMAC 
MDA-MB-453 
cell line 
AR 
Protein expression ↑ ↑ - - - - - - 
Via AR yes yes - - - - - - 
ERβ 
mRNA expression ↑ ↑ ↑ ↑ ↑ ↓ - - 
Via AR yes yes yes yes yes no - - 
MCF-7 BUS 
cell line 
AR 
Protein expression ↑ ↑ - - - - - - 
Via AR yes yes - - - - - - 
ERβ 
mRNA expression ↑ ↑ N.D. N.D. N.D. N.D. N.D. N.D. 
Via AR ? ? N.D. N.D. N.D. N.D. N.D. N.D. 
ERα 
mRNA expression ↓ ↓ - ↓ - ↓ - - 
Via AR yes yes - no - yes - - 
Protein expression - - - ↓ - - - - 
Via AR - - - no - - - - 
  
Upregulation (↑), downregulation (↓), no effect (−), not determined (N.D.), unanswered (?). 
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Table 4.2. Summary of the effects of androgens and progestogens on breast cancer cell proliferation. 
 
Androgens Androgenic progestins Anti-androgenic progestins 
Mib DHT MPA NET-A LNG P4 NES 
MCF-7 BUS 
cell line 
Proliferation ↑ ↑ ↑ ↑ ↑ ↑ ↑ 
Steroid 
receptor 
required: 
AR yes yes yes yes yes no no 
ER ? ? ? ? ? ? ? 
PR ? ? ? ? ? ? ? 
GR ? ? ? ? ? ? ? 
T47D  
cell line 
Proliferation ↑ ↑ ↑ ↑ ↑ ↑ ↑ 
Steroid 
receptor 
required: 
AR yes yes yes yes yes no no 
ER no no no yes yes no no 
PR yes no yes yes yes yes yes 
GR ? ? ? ? ? ? ? 
 
Upregulation (↑), downregulation (↓), no effect (−), unanswered (?).
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4.10 Future work 
A major limitation of the current study is the fact that we were unable to reproduce our results 
showing that Mib and DHT increased ERβ mRNA expression in the MCF-7 BUS and T47D breast 
cancer cell lines. As it has been suggested that experiments in adherent cancer cell lines should be 
performed within the first ten passages of a new freezer stock (Masters, 2000), future experiments 
should be performed within this timeline. A further limitation of the study is the fact that results from 
the MTT cell viability assay in the MDA-MB-453 cell line are from a single experiment. To validate 
these findings, at least two more biological repeats of this experiment are required. In addition, an in 
vitro mammalian two-hybrid assay was used to assess the AR N/C interaction, which does not 
evaluate the full-length human AR. Thus, quantitative fluorescence resonance energy transfer (FRET) 
assays can be used to investigate the AR N/C interaction via the full-length human AR in living cells. 
This can be achieved by tagging the NTD and COOH-terminal of the AR with the FRET couple 
cyano fluorescent protein (CFP) and yellow fluorescent protein (YFP). The fluorescence signal upon 
excitation of CFP or YFP can then be measured with a fluorescence microscope as previously 
described (Schaufele et al., 2005).  
 
Rizza et al. (2014) showed that the androgen-activated AR increased ERβ expression by binding to 
an ARE in the promoter of the human ERβ gene. Electrophoretic mobility shift assays (EMSA) and 
chromatin immunoprecipitation (ChIP) assays can be performed to evaluate whether the progestin-
bound AR also occupies this ARE cis-element. EMSA is an in vitro method used to detect whether a 
protein binds to a given DNA sequence, while the ChIP assay is used to evaluate the interaction 
between the protein and the DNA in the cell (Smith and Humphries, 2009; Nguyen-Duc et al., 2012). 
We showed that the Mib- and DHT-activated AR decreased ERα mRNA expression. We 
hypothesized that this downregulation occurs via the ERα tethering to DNA-bound transcription 
factors like AP-1 (McDonnell and Norris, 2002). A combination of siRNA technology and ChIP 
assays can be used to investigate whether the Mib- and DHT-activated AR and AP-1 are co-recruited 
to the AP-1 cis-element in the ERα gene promoter (Carroll et al., 2006). Progestins are often 
administered to women in combination with an estrogen (Greendale et al., 1999; Hickey et al., 2012). 
Thus, future studies should also investigate the effects of E2 and progestin combinations on ERα and 
ERβ expression, as well as on breast cancer cell proliferation. Given that the role of the ER and PR 
in MCF-7 BUS cells, and GR in either MCF-7 BUS or T47D cell lines (Figure 3.5), could not be 
assessed using receptor antagonists, silencing the expression of a particular steroid receptor by siRNA 
technology may be a better strategy in future studies. Finally, to confirm that the findings of this study 
Stellenbosch University  https://scholar.sun.ac.za
  
 
71 
are clinically relevant, it is crucial that future studies evaluate whether the effects of the androgens 
and progestins on ERα and ERβ expression can be extended into primary human breast tumours.
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A.1 Bacterial media 
Luria Bertani (LB) medium 
10 g NaCl 
10 g Tryptone 
5 g Yeast extract 
Adjust to a final volume of 1 L using reverse osmosis (RO) H2O. 
Sterilize by autoclaving and store at room temperature. 
 
LB Agar plates 
LB medium 
15 g/L Bacterial agar 
Ampicillin (final concentration 50 µg/mL) 
 
A.2 Cell lysis 
10X Tris-phosphate-EDTA (TPE) buffer 
108 g Tris (hydroxymethyl) aminomethane 
15.5 mL 85% (v/v) Phosphoric acid 
40 mL 0.5 M EDTA (pH 8.0) 
Adjust to a final volume of 1 L using RO H2O. 
Sterilize by autoclaving and store at room temperature. 
 
Passive Lysis Buffer 
0.5 mL Triton X-100 
25 mL Glycerol 
7 mL 1X TPE buffer 
720 µL 0.5 M EDTA 
Adjust to a final volume of 250 mL using RO H2O and store at 4°C. 
 
A.3 SDS-PAGE and western blotting 
10% (w/v) SDS 
Dissolve 10 g SDS in 100 mL RO H2O at 68°C. 
Store at room temperature. 
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2X Laemmli buffer 
1 mL 1M Tris-HCl (pH 6.8) 
5 mL 10% (w/v) SDS 
2 mL Glycerol 
500 µL β-mercaptoethanol 
0.01 g Bromophenol blue 
Adjust to a final volume of 25 mL with RO H2O and store at -20°C. 
 
10X SDS-PAGE Running Buffer 
20 g SDS 
60.6 g Tris 
288.2 g Glycine 
Adjust to a final volume of 2 L using RO H2O and store at room temperature. 
 
1X Transfer Buffer 
6.06 g Tris 
28.83 g Glycine 
200 mL Methanol 
Adjust to a final volume of 2 L using RO H2O and store at 4°C. 
 
10X Tris buffered saline (TBS) (pH 7.5) 
Dissolve 60.5 g Tris and 87.6 g NaCl in 800 mL RO H2O. 
Adjust the pH to 7.5 
Adjust to a final volume of 1 L using RO H2O and store at 4°C. 
 
TBS-Tween (TBST) 
100 mL 10X TBS buffer 
1 mL Tween 20 
Adjust to a final volume of 1 L using RO H2O and store at 4°C. 
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A.4  Agarose gel electrophoresis 
50X Tris-acetate-EDTA (TAE) buffer 
Dissolve 242.2 g Tris in 700 mL RO H2O. 
Add 57.1 mL glacial acetic acid and 100 mL 0.5 M EDTA (pH 8.2). 
Adjust to a final volume of 1 L using RO H2O and store at room temperature. 
 
10X Morpholinopropanesulfonic acid (MOPS) running buffer 
Dissolve 83.71 g MOPS in 800 mL DEPC-treated H2O. 
Add 33.4 mL 3 M NaOAc and 20 mL 0.5 M EDTA RNase-free stock solutions. 
Adjust pH to 7.0 
Adjust to a final volume of 1 L using DEPC-treated H2O. 
Sterilize by autoclaving and store in a dark place at 4°C. 
 
2X Formaldehyde RNA loading buffer 
0.071 g Bromophenol blue 
1 mL Glycerol 
1.5 mL 10X MOPS 
2.6 mL Formaldehyde 
7.3 mL Formamide 
Adjust to a final volume of 15 mL using DEPC-treated H2O. 
Prepare 1 mL aliquots and store at -20°C. 
Add 2.5 µL ethidium bromide to each 1 mL aliquot before use. 
 
A.5 Cell viability assays 
MTT Solution (5 mg/mL) 
Dissolve 5 mg MTT in 1 mL sterile 1X PBS. 
Filter sterilize. 
 
A.6 Charcoal-stripping of FCS 
Lipophilic materials such as growth factors, hormones and cytokines, which may affect hormone- 
induced responses and subsequently impact experimental results, are removed from FCS using 
dextran-treated charcoal (Lau and Chang, 2014).  
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Charcoal-stripping Buffer 
250 mL 1 M Sucrose 
1.5 mL 1 M Magnesium chloride hexahydrate 
10 mL 1 M HEPES 
2.5 g Norit-A® (activated charcoal) 
0.025 g Dextran 
Adjust to final volume of 1 L using Milli-Q® H2O, and stir overnight at 4°C. 
 Store at 4°C. 
 
1. Activated dextran-treated charcoal was collected from 500 mL charcoal-stripping buffer by 
centrifugation at 500 x g for 30 minutes at 4°C.  
2. The supernatant was discarded and the charcoal pellet resuspended in 50 mL FCS, which was 
stirred overnight at 4°C.  
3. The next day, the charcoal was removed from the FCS by centrifugation at 500 x g for 30 minutes 
at 4°C.  
4. Steps 1-3 were repeated using the same FCS sample.  
5. Excess charcoal was removed from the stripped FCS by filter-sterilization. 
 
A.7 Heat-inactivation of FCS 
Heat-inactivation of FCS leads to the inactivation of the complement system as well as the destruction 
of heat labile growth factors, vitamins, amino acids, and hormones that may be present (Ayache et 
al., 2006). To heat-inactivate FCS, the serum was thawed and subsequently heated to 56°C for 30 
minutes. 
Stellenbosch University  https://scholar.sun.ac.za
  
 
 
 
Addendum B 
Additional Data
Stellenbosch University  https://scholar.sun.ac.za
  
 
107 
B.1 All cell lines used in this study were mycoplasma negative. 
 
        
     
 
 
Figure B.1. Mycoplasma negative (A) COS-1, (B) HEK-293, (C) MCF-7 BUS, (D) T47D and (E) MDA-
MB-453 cells. Cells were stained with the DNA Hoechst 33258 dye (Sigma-Aldrich, South Africa). Only 
DNA-containing nuclei are stained with the Hoechst dye. The fluorescence was visualized and the images 
captured using the Olympus IX81 inverted fluorescence microscope (Life Science Solutions, South Africa). 
A B 
C D 
E 
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B.2 RU486 antagonizes the PR, but not GR, in the T47D breast cancer cells, but does 
not elicit antagonist activity in the MCF-7 BUS cell line.  
 
 
  
 
Figure B.2. RU486 increases proliferation of both MCF-7 BUS and T47D cells, and acts as a PR, but not 
GR antagonist in the T47D cells. The human (A) MCF-7 BUS and (B) T47D breast cancer cells were treated 
for 72 hours with either 0.2% (v/v) EtOH (vehicle), 10 nM of the GR-specific agonist, Dex, or the PR-specific 
agonist, R5020, in the absence and presence of 1 µM RU486. The medium was aspirated and cells were re-
treated for an additional 44 hours. Cell proliferation was measured using the MTT cell viability assay. Results 
are represented as fold proliferation relative to the vehicle control. The results shown are the averages (± SEM) 
of at least three independent experiments with each condition performed in triplicate. Statistical analysis was 
performed using two-way ANOVA with Bonferroni’s (compares all pairs of columns) as post-test. 
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B.3 ICI significantly decreases the viability of the MCF-7 BUS breast cancer cell line, 
but not the T47D cell line.  
 
             
 
Figure B.3. ICI significantly decreases the viability of the MCF-7 BUS cells, but not the T47D cells. The 
human (A) MCF-7 BUS and (B) T47D breast cancer cells were treated for 72 hours with either 0.2% (v/v) 
EtOH (vehicle) or 10 nM of the ER-agonist, E2, in the absence and presence of 1 µM of the ER antagonist, 
ICI. The medium was aspirated and cells were re-treated for an additional 44 hours. Cell proliferation was 
measured using the MTT cell viability assay. Results are represented as fold proliferation relative to the vehicle 
control. The results shown are the averages (± SEM) of at least three independent experiments with each 
condition performed in triplicate. Statistical analysis was performed using two-way ANOVA with 
Bonferroni’s (compares all pairs of columns) as post-test. 
 
B.4 The commercial ERβ antibody from Abcam (EPR20743) is not specific for ERβ. 
 
 
Figure B.4. Western blot analysis indicating non-specificity of the commercial ERβ antibody 
(EPR20743). Protein lysates were analyzed by western blotting using primary antibodies specific for ERβ and 
GAPDH (loading control). HEK-293 cells transiently transfected with an expression vector for ERβ was used 
as a positive control, while untransfected COS-1 cells were used as a negative control. A representative western 
blot of at least two independent experiments is shown. 
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B.5 ERβ mimics the proliferative effects of ERα in the MDA-MB-453 breast cancer 
cells, while E2-induced proliferation is decreased when ERα and ERβ are co-expressed.  
 
 
 
 
Figure B.5. ERβ mimics the proliferative effects of ERα in the absence of ERα expression, while E2-
induced proliferation is decreased when ERα and ERβ are co-expressed. The human MDA-MB-453 breast 
cancer cells were either left untransfected or transiently transfected with an expression vector for human ERα. 
All cells were treated for 72 hours with either 0.1% (v/v) EtOH (vehicle) or increasing concentrations of E2. 
The medium was aspirated and cells were re-treated for an additional 44 hours. Cell proliferation was measured 
using the MTT cell viability assay. Results are represented as fold proliferation relative to the vehicle control. 
The result shown is the averages (± SD) of a single experiment with each condition performed in triplicate. 
(B) The data from (A) was re-plotted to directly compare the effects between transfection conditions. Statistical 
analysis was performed using two-way ANOVA with Bonferroni’s (compares all pairs of columns) as post-
test. 
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B.6 Hydroxyflutamide, but not Bicalutamide, antagonizes the proliferative effects of 
androgens and progestins in T47D breast cancer cells. 
 
 
Figure B.6. The AR antagonist, Bicalutamide, does not elicit antagonist activity in the T47D breast 
cancer cell line. The human T47D breast cancer cells were treated for 72 hours with either 0.2% (v/v) EtOH 
(vehicle) or 10 nM Mib, DHT, P4, MPA, NET-A, LNG or NES, in the absence and presence of either 10 µM 
Bicalutamide (Bical) or 10 µM hydroxyflutamide (OHF). The medium was aspirated and cells were re-treated 
for an additional 44 hours. Cell proliferation was measured using the MTT cell viability assay. Results are 
represented as fold proliferation relative to the vehicle control. The results shown are the averages (± SEM) of 
at least three independent experiments with each condition performed in triplicate. Statistical analysis was 
performed using two-way ANOVA with Bonferroni’s (compares all pairs of columns) as post-test.
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Introduction 
Real-time qPCR is a highly sensitive and powerful technique used to quantitatively measure relative 
mRNA gene expression (Wong and Medrano, 2005). This method involves the amplification of DNA 
using a fluorescent dye such as SYBR Green, that binds to the minor groove of double stranded DNA 
(Lekanne Deprez et al., 2002). The amplified DNA can thus be monitored in realtime by measuring 
the fluorescence (Lekanne Deprez et al., 2002). The detected fluorescence intensity is directly 
proportional to the amount of amplified DNA (Arya et al., 2005). The qPCR reaction can be divided 
into four major phases: linear ground phase, early exponential phase, log-linear phase and the plateau 
phase (Wong and Medrano, 2005; Fraga et al., 2008). The linear ground phase is the phase where the 
qPCR reaction is initiated (first 10 – 15 cycles) and the fluorescence emitted is below background 
levels. The amplification cycle number at which the fluorescence exceeds the background 
fluorescence is known as the quantification cycle (Cq) (Pfaffl, 2001). The log-linear phase is where 
the amplicon increases exponentially, while the plateau phase occurs when the qPCR reaction 
components become depleted. In this study, qPCR was used to evaluate the relative mRNA 
expression of ERα and ERβ following treatment with test compounds.  
The first crucial step was the isolation of high quality, intact RNA, as poor quality RNA negatively 
influences experimental results. Following the isolation of total RNA, the purity thereof was assessed 
by measuring the optical density (OD), while the RNA integrity was analyzed on a 1% (w/v) 
denaturing formaldehyde agarose gel. A 260/280 ratio greater than or equal to 1.9 is indicative of 
pure RNA (Sambrook et al., 1989), while intact total RNA is observed as two clear bands, the 28S 
and 18S bands, which represent the ribosomal RNA subunits. The 28S band should be approximately 
twice the intensity of the 18S RNA band. Representative 1% (w/v) denaturing formaldehyde agarose 
gels are shown in Figure C.1.  
 
 
 
 
Figure C.1 legend on next page. 
A B C 
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Figure C.1. A representative 1% (w/v) denaturing formaldehyde agarose gel showing intact RNA in (A) 
MCF-7 BUS, (B) T47D and (C) MDA-MB-453 cells. Total RNA was isolated as described in Chapter 2, 
Section 2.5. One µg RNA was loaded onto the agarose gel, and the RNA was visualized by ethidium bromide 
staining. Lane 1: Cells treated with EtOH (vehicle control); Lane 2: Cells treated with 10 nM Mib; Lane 3: 
Cells treated with 10 nM DHT. 
 
The intact total RNA was subsequently reverse transcribed to synthesize cDNA as described in 
Chapter 2, Section 2.6. Next, real-time qPCR was performed as described in Chapter 2, Section 2.7.  
 
Determination of primer pair efficiency 
The efficiency of real-time qPCR is dependent of the amplification efficiency of the primer pair used, 
which is generally assumed to be two, as the amount of DNA present in a sample theoretically doubles 
with each PCR cycle (Pfaffl, 2001; Wong and Medrano, 2005). As this may not always be the case, 
the primer efficiencies of ERα and ERβ were determined before the relative gene expression was 
calculated. To achieve this, a serial dilution of a single cDNA sample was prepared and each dilution 
analyzed in triplicate. PCR-grade water was used as negative control to confirm that there was no 
contamination or primer self-amplification. Standard curves (Figure C.2) were then generated by 
plotting the Cq value against the log cDNA concentration. The slope of the curve was then determined 
and used to calculate the primer efficiency (E) using the following mathematical equation (Pfaffl, 
2001): 
     E = 10(&' ()*+,)    (Equation 1) 
 
The primer efficiencies reported for the ERα, ERβ and glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) primer pairs (Table C.1) are the averages of two independent experiments. The efficiency 
for the ERα primer pair was determined in MCF-7 BUS cells, while the ERβ primer efficiencies were 
investigated in the T47D and MDA-MB-453 cells. Meghan Perkins in the Africander laboratory 
previously determined the efficiency for the ERβ primer pair in the MCF-7 BUS cells. The efficiency 
for the GAPDH primer pair was determined in the MDA-MB-453 cells, while Renate Louw-du Toit 
in the Africander laboratory previously determined efficiencies for this primer pair in the MCF-7 
BUS and T47D cells. 
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Table C.1. Efficiencies for primer pairs used in this study. 
Primer pair Cell line Primer efficiency (E) 
ERα MCF-7 BUS 2.02 
ERβ 
MCF-7 BUS 1.94 
T47D 1.86 
MDA-MB-453 1.99 
GAPDH 
MCF-7 BUS 1.86 
T47D 1.89 
MDA-MB-453 1.76 
 
 
 
 
 
Figure C.2 continued on next page. 
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Figure C.2. Representative standard curves for the (A) ERα, (B and C) ERβ and (D) GAPDH primer 
pairs. Standard curves were generated by plotting the Cq value against the log concentration of cDNA. The 
slope determined from these standard curves were used to calculate the efficiency of the primer pairs used in 
the (A) MCF-7 BUS, (B) T47D as well as the (C and D) MDA-MB-453 cell lines.  
 
Melting curve analysis 
In real-time qPCR, each PCR product has a unique melting temperature, which is dependent on the 
nucleotide content and size of the desired amplicon (Ririe et al., 1997). Analysis of the melting peak 
of a sample confirms the presence of a single PCR product. The melting curve analysis was performed 
by varying the temperature between 50°C and 95°C, gradually increasing the temperature by 2.2°C, 
and continuously measuring the fluorescence after each temperature-increase step. Using the 
LightCycler® 96 software, a melting curve was plotted with the negative derivative of fluorescence 
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over temperature (-dF/dT) on the y-axis and temperature (°C) on the x-axis (Figure C.3). The presence 
of more than one peak on the melting curve is indicative of primer-dimers or other non-specific PCR 
products (Ririe et al., 1997; Fraga et al., 2008). 
 
 
 
 
 
Figure C.3 continued on next page. 
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Figure C.3. Melting curve analysis for (A) ERα, (B) ERβ and (C) GAPDH. Melting curves were generated 
using the LightCycler® 96 software. (A) ERα gene expression was investigated in MCF-7 BUS cells, while 
(B) ERβ and (C) GAPDH gene expression was investigated in MDA-MB-453 cells. Samples treated with 
EtOH (vehicle control) are indicated in blue, while the red curves indicate the negative controls containing no 
template.  
 
Single product amplification was also confirmed by performing agarose gel electrophoresis. 
Representative agarose gels are shown in Figure C.4. 
 
 
 
 
Figure C.4 continued on next page. 
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Figure C.4. Representative agarose gels indicating the real-time qPCR end products of (A) ERα, (B) 
ERβ and (C) GAPDH. PCR end products were subjected to agarose gel electrophoresis (2% (w/v)) and 
visualized using the Nancy-520 (Sigma-Aldrich, South Africa) nucleic acid stain. (A) M: Ultra-Low Range 
DNA Ladder (Thermo Fisher Scientific, South Africa); (B and C) M: 100 bp DNA Ladder (Thermo Fisher 
Scientific, South Africa); Lane 1: Sample treated with EtOH (vehicle control); Lane 2: No template negative 
control. 
 
Determination of relative gene expression values 
The relative expression levels (R) of the target genes were calculated using the mathematical equation 
described by Pfaffl (2001), and expressed as the ratio of the target gene expression relative to the 
expression of the reference gene, GAPDH (Equation 2): 
  
  . = 	 (0123451	4565)Δ89123451	4565	(:;613;<−>2?@<5)(035A5356:5	4565)Δ8935A5356:5	4565	(:;613;<−>2?@<5)  (Equation 2) 
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The R value is dependent on the efficiency of the primer pair (calculated using Equation 1) and the 
change in quantification cycle (∆Cq). The value for ∆Cq was calculated by subtracting the Cq value of 
the treated sample from the Cq value of the vehicle control sample (EtOH). A R value of one indicates 
that there is no difference between samples treated with test compounds and samples treated with 
EtOH. A R value greater than one indicates the upregulation of the target gene, while a value smaller 
than one indicates inhibition (Pfaffl, 2001).  
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